<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<html>
 <body>
  <pubmedarticleset>
   <pubmedarticle>
    <medlinecitation owner="NLM" status="Publisher">
     <pmid version="1">
      32305011
     </pmid>
     <daterevised>
      <year>
       2020
      </year>
      <month>
       04
      </month>
      <day>
       18
      </day>
     </daterevised>
     <article pubmodel="Print-Electronic">
      <journal>
       <issn issntype="Electronic">
        1879-0852
       </issn>
       <journalissue citedmedium="Internet">
        <volume>
         132
        </volume>
        <pubdate>
         <year>
          2020
         </year>
         <month>
          Apr
         </month>
         <day>
          06
         </day>
        </pubdate>
       </journalissue>
       <title>
        European journal of cancer (Oxford, England : 1990)
       </title>
       <isoabbreviation>
        Eur. J. Cancer
       </isoabbreviation>
      </journal>
      <articletitle>
       Conducting phase 1 cancer clinical trials during the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-related disease pandemic.
      </articletitle>
      <pagination>
       <medlinepgn>
        8-10
       </medlinepgn>
      </pagination>
      <elocationid eidtype="pii" validyn="Y">
       S0959-8049(20)30164-7
      </elocationid>
      <elocationid eidtype="doi" validyn="Y">
       10.1016/j.ejca.2020.03.023
      </elocationid>
      <authorlist completeyn="Y">
       <author validyn="Y">
        <lastname>
         Tarantino
        </lastname>
        <forename>
         Paolo
        </forename>
        <initials>
         P
        </initials>
        <affiliationinfo>
         <affiliation>
          European Institute of Oncology, IRCCS, Milan, Italy; University of Milan, Milan, Italy.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Trapani
        </lastname>
        <forename>
         Dario
        </forename>
        <initials>
         D
        </initials>
        <affiliationinfo>
         <affiliation>
          European Institute of Oncology, IRCCS, Milan, Italy.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Curigliano
        </lastname>
        <forename>
         Giuseppe
        </forename>
        <initials>
         G
        </initials>
        <affiliationinfo>
         <affiliation>
          European Institute of Oncology, IRCCS, Milan, Italy; University of Milan, Milan, Italy. Electronic address: Giuseppe.curigliano@ieo.it.
         </affiliation>
        </affiliationinfo>
       </author>
      </authorlist>
      <language>
       eng
      </language>
      <publicationtypelist>
       <publicationtype ui="D016422">
        Letter
       </publicationtype>
      </publicationtypelist>
      <articledate datetype="Electronic">
       <year>
        2020
       </year>
       <month>
        04
       </month>
       <day>
        06
       </day>
      </articledate>
     </article>
     <medlinejournalinfo>
      <country>
       England
      </country>
      <medlineta>
       Eur J Cancer
      </medlineta>
      <nlmuniqueid>
       9005373
      </nlmuniqueid>
      <issnlinking>
       0959-8049
      </issnlinking>
     </medlinejournalinfo>
     <citationsubset>
      IM
     </citationsubset>
     <coistatement>
      Conflict of interest statement P.T. and D.T. declare no potential conflicts of interest related to this work. G.C. reports receiving honoraria for a speaker and consultancy or advisory rule from Roche, Pfizer, Novartis, Seattle Genetics, Lilly, Ellipses Pharma, Foundation Medicine and Samsung.
     </coistatement>
    </medlinecitation>
    <pubmeddata>
     <history>
      <pubmedpubdate pubstatus="received">
       <year>
        2020
       </year>
       <month>
        03
       </month>
       <day>
        30
       </day>
      </pubmedpubdate>
      <pubmedpubdate pubstatus="accepted">
       <year>
        2020
       </year>
       <month>
        03
       </month>
       <day>
        31
       </day>
      </pubmedpubdate>
      <pubmedpubdate pubstatus="entrez">
       <year>
        2020
       </year>
       <month>
        4
       </month>
       <day>
        19
       </day>
       <hour>
        6
       </hour>
       <minute>
        0
       </minute>
      </pubmedpubdate>
      <pubmedpubdate pubstatus="pubmed">
       <year>
        2020
       </year>
       <month>
        4
       </month>
       <day>
        19
       </day>
       <hour>
        6
       </hour>
       <minute>
        0
       </minute>
      </pubmedpubdate>
      <pubmedpubdate pubstatus="medline">
       <year>
        2020
       </year>
       <month>
        4
       </month>
       <day>
        19
       </day>
       <hour>
        6
       </hour>
       <minute>
        0
       </minute>
      </pubmedpubdate>
     </history>
     <publicationstatus>
      aheadofprint
     </publicationstatus>
     <articleidlist>
      <articleid idtype="pubmed">
       32305011
      </articleid>
      <articleid idtype="pii">
       S0959-8049(20)30164-7
      </articleid>
      <articleid idtype="doi">
       10.1016/j.ejca.2020.03.023
      </articleid>
     </articleidlist>
    </pubmeddata>
   </pubmedarticle>
   <pubmedarticle>
    <medlinecitation owner="NLM" status="Publisher">
     <pmid version="1">
      32304435
     </pmid>
     <daterevised>
      <year>
       2020
      </year>
      <month>
       04
      </month>
      <day>
       18
      </day>
     </daterevised>
     <article pubmodel="Print-Electronic">
      <journal>
       <issn issntype="Electronic">
        1537-453X
       </issn>
       <journalissue citedmedium="Internet">
        <pubdate>
         <year>
          2020
         </year>
         <month>
          Apr
         </month>
         <day>
          16
         </day>
        </pubdate>
       </journalissue>
       <title>
        American journal of clinical oncology
       </title>
       <isoabbreviation>
        Am. J. Clin. Oncol.
       </isoabbreviation>
      </journal>
      <articletitle>
       The Impact of the COVID-19 Pandemic on Cancer Patients.
      </articletitle>
      <elocationid eidtype="doi" validyn="Y">
       10.1097/COC.0000000000000712
      </elocationid>
      <abstract>
       <abstracttext>
        In December 2019, a novel coronavirus called severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) caused an outbreak of coronavirus disease 2019 (COVID-19). Severe complications have been reported to occur in 33% of patients with COVID-19 and include acute respiratory distress syndrome, acute renal failure, acute respiratory injury, septic shock, and severe pneumonia. Currently, there is no specific treatment or approved vaccine against COVID-19 and many clinical trials are currently investigating potential medications to treat COVID-19. The immunosuppressed status of some cancer patients (whether caused by the disease itself or the treatment) increases their risk of infection compared with the general population. This short review aims to focus on the impact of COVID-19 on a cancer patient and discuss management options and recommendation in addition to highlighting the currently available clinical guidelines and resources.
       </abstracttext>
      </abstract>
      <authorlist completeyn="Y">
       <author validyn="Y">
        <lastname>
         Al-Quteimat
        </lastname>
        <forename>
         Osama M
        </forename>
        <initials>
         OM
        </initials>
        <affiliationinfo>
         <affiliation>
          Pharmacy Services Department, Cleveland Clinic Abu Dhabi, Abu Dhabi, UAE.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Amer
        </lastname>
        <forename>
         Amer Mustafa
        </forename>
        <initials>
         AM
        </initials>
        <affiliationinfo>
         <affiliation>
          Inpatient Pharmacist, The Specialty Hospital, Amman, Jordan.
         </affiliation>
        </affiliationinfo>
       </author>
      </authorlist>
      <language>
       eng
      </language>
      <publicationtypelist>
       <publicationtype ui="D016428">
        Journal Article
       </publicationtype>
      </publicationtypelist>
      <articledate datetype="Electronic">
       <year>
        2020
       </year>
       <month>
        04
       </month>
       <day>
        16
       </day>
      </articledate>
     </article>
     <medlinejournalinfo>
      <country>
       United States
      </country>
      <medlineta>
       Am J Clin Oncol
      </medlineta>
      <nlmuniqueid>
       8207754
      </nlmuniqueid>
      <issnlinking>
       0277-3732
      </issnlinking>
     </medlinejournalinfo>
     <citationsubset>
      IM
     </citationsubset>
    </medlinecitation>
    <pubmeddata>
     <history>
      <pubmedpubdate pubstatus="entrez">
       <year>
        2020
       </year>
       <month>
        4
       </month>
       <day>
        19
       </day>
       <hour>
        6
       </hour>
       <minute>
        0
       </minute>
      </pubmedpubdate>
      <pubmedpubdate pubstatus="pubmed">
       <year>
        2020
       </year>
       <month>
        4
       </month>
       <day>
        19
       </day>
       <hour>
        6
       </hour>
       <minute>
        0
       </minute>
      </pubmedpubdate>
      <pubmedpubdate pubstatus="medline">
       <year>
        2020
       </year>
       <month>
        4
       </month>
       <day>
        19
       </day>
       <hour>
        6
       </hour>
       <minute>
        0
       </minute>
      </pubmedpubdate>
     </history>
     <publicationstatus>
      aheadofprint
     </publicationstatus>
     <articleidlist>
      <articleid idtype="pubmed">
       32304435
      </articleid>
      <articleid idtype="doi">
       10.1097/COC.0000000000000712
      </articleid>
     </articleidlist>
    </pubmeddata>
   </pubmedarticle>
   <pubmedarticle>
    <medlinecitation owner="NLM" status="Publisher">
     <pmid version="1">
      32303607
     </pmid>
     <daterevised>
      <year>
       2020
      </year>
      <month>
       04
      </month>
      <day>
       18
      </day>
     </daterevised>
     <article pubmodel="Print-Electronic">
      <journal>
       <issn issntype="Electronic">
        1468-3288
       </issn>
       <journalissue citedmedium="Internet">
        <pubdate>
         <year>
          2020
         </year>
         <month>
          Apr
         </month>
         <day>
          17
         </day>
        </pubdate>
       </journalissue>
       <title>
        Gut
       </title>
       <isoabbreviation>
        Gut
       </isoabbreviation>
      </journal>
      <articletitle>
       British Society of Gastroenterology guidance for management of inflammatory bowel disease during the COVID-19 pandemic.
      </articletitle>
      <elocationid eidtype="pii" validyn="Y">
       gutjnl-2020-321244
      </elocationid>
      <elocationid eidtype="doi" validyn="Y">
       10.1136/gutjnl-2020-321244
      </elocationid>
      <abstract>
       <abstracttext>
        The COVID-19 pandemic is putting unprecedented pressures on healthcare systems globally. Early insights have been made possible by rapid sharing of data from China and Italy. In the UK, we have rapidly mobilised inflammatory bowel disease (IBD) centres in order that preparations can be made to protect our patients and the clinical services they rely on. This is a novel coronavirus; much is unknown as to how it will affect people with IBD. We also lack information about the impact of different immunosuppressive medications. To address this uncertainty, the British Society of Gastroenterology (BSG) COVID-19 IBD Working Group has used the best available data and expert opinion to generate a risk grid that groups patients into highest, moderate and lowest risk categories. This grid allows patients to be instructed to follow the UK government's advice for shielding, stringent and standard advice regarding social distancing, respectively. Further considerations are given to service provision, medical and surgical therapy, endoscopy, imaging and clinical trials.
       </abstracttext>
       <copyrightinformation>
        © Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.
       </copyrightinformation>
      </abstract>
      <authorlist completeyn="Y">
       <author validyn="Y">
        <lastname>
         Kennedy
        </lastname>
        <forename>
         Nicholas A
        </forename>
        <initials>
         NA
        </initials>
        <identifier source="ORCID">
         http://orcid.org/0000-0003-4368-1961
        </identifier>
        <affiliationinfo>
         <affiliation>
          Royal Devon and Exeter NHS Foundation Trust, Exeter, UK.
         </affiliation>
        </affiliationinfo>
        <affiliationinfo>
         <affiliation>
          University of Exeter, Exeter, UK.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Jones
        </lastname>
        <forename>
         Gareth-Rhys
        </forename>
        <initials>
         GR
        </initials>
        <identifier source="ORCID">
         http://orcid.org/0000-0001-7355-2357
        </identifier>
        <affiliationinfo>
         <affiliation>
          University of Edinburgh, Edinburgh, UK.
         </affiliation>
        </affiliationinfo>
        <affiliationinfo>
         <affiliation>
          Western General Hospital, Edinburgh, UK.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Lamb
        </lastname>
        <forename>
         Christopher A
        </forename>
        <initials>
         CA
        </initials>
        <identifier source="ORCID">
         http://orcid.org/0000-0002-7271-4956
        </identifier>
        <affiliationinfo>
         <affiliation>
          Newcastle University, Newcastle upon Tyne, UK.
         </affiliation>
        </affiliationinfo>
        <affiliationinfo>
         <affiliation>
          Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, UK.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Appleby
        </lastname>
        <forename>
         Richard
        </forename>
        <initials>
         R
        </initials>
        <identifier source="ORCID">
         http://orcid.org/0000-0001-5887-8922
        </identifier>
        <affiliationinfo>
         <affiliation>
          Chelsea and Westminster Hospital NHS Foundation Trust, London, UK.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Arnott
        </lastname>
        <forename>
         Ian
        </forename>
        <initials>
         I
        </initials>
        <identifier source="ORCID">
         http://orcid.org/0000-0003-3352-9253
        </identifier>
        <affiliationinfo>
         <affiliation>
          Western General Hospital, Edinburgh, UK.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Beattie
        </lastname>
        <forename>
         R Mark
        </forename>
        <initials>
         RM
        </initials>
        <identifier source="ORCID">
         http://orcid.org/0000-0003-4721-0577
        </identifier>
        <affiliationinfo>
         <affiliation>
          Southampton Children's Hospital, University Hospital Southampton NHS Foundation Trust, Southampton, UK.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Bloom
        </lastname>
        <forename>
         Stuart
        </forename>
        <initials>
         S
        </initials>
        <identifier source="ORCID">
         http://orcid.org/0000-0002-6361-4662
        </identifier>
        <affiliationinfo>
         <affiliation>
          University College London Hospitals NHS Foundation Trust, London, UK.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Brooks
        </lastname>
        <forename>
         Alenka J
        </forename>
        <initials>
         AJ
        </initials>
        <identifier source="ORCID">
         http://orcid.org/0000-0001-7162-7845
        </identifier>
        <affiliationinfo>
         <affiliation>
          Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, UK.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Cooney
        </lastname>
        <forename>
         Rachel
        </forename>
        <initials>
         R
        </initials>
        <identifier source="ORCID">
         http://orcid.org/0000-0003-3710-157X
        </identifier>
        <affiliationinfo>
         <affiliation>
          Queen Elizabeth Hospital Birmingham NHS Foundation Trust, Birmingham, UK.
         </affiliation>
        </affiliationinfo>
        <affiliationinfo>
         <affiliation>
          University of Birmingham, Birmingham, UK.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Dart
        </lastname>
        <forename>
         Robin J
        </forename>
        <initials>
         RJ
        </initials>
        <identifier source="ORCID">
         http://orcid.org/0000-0003-3470-8210
        </identifier>
        <affiliationinfo>
         <affiliation>
          King's College London, London, UK.
         </affiliation>
        </affiliationinfo>
        <affiliationinfo>
         <affiliation>
          The Royal Free Hospital, London, UK.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Edwards
        </lastname>
        <forename>
         Cathryn
        </forename>
        <initials>
         C
        </initials>
        <identifier source="ORCID">
         http://orcid.org/0000-0002-5550-9184
        </identifier>
        <affiliationinfo>
         <affiliation>
          Torbay and South Devon NHS Foundation Trust, Torquay, UK.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Fraser
        </lastname>
        <forename>
         Aileen
        </forename>
        <initials>
         A
        </initials>
        <identifier source="ORCID">
         http://orcid.org/0000-0001-6462-5091
        </identifier>
        <affiliationinfo>
         <affiliation>
          University Hospitals Bristol NHS Foundation Trust, Bristol, UK.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Gaya
        </lastname>
        <forename>
         Daniel R
        </forename>
        <initials>
         DR
        </initials>
        <identifier source="ORCID">
         http://orcid.org/0000-0003-1942-7568
        </identifier>
        <affiliationinfo>
         <affiliation>
          Glasgow Royal Infirmary, Glasgow, UK.
         </affiliation>
        </affiliationinfo>
        <affiliationinfo>
         <affiliation>
          University of Glasgow, Glasgow, UK.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Ghosh
        </lastname>
        <forename>
         Subrata
        </forename>
        <initials>
         S
        </initials>
        <identifier source="ORCID">
         http://orcid.org/0000-0002-1713-7797
        </identifier>
        <affiliationinfo>
         <affiliation>
          Queen Elizabeth Hospital Birmingham NHS Foundation Trust, Birmingham, UK.
         </affiliation>
        </affiliationinfo>
        <affiliationinfo>
         <affiliation>
          University of Birmingham, Birmingham, UK.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Greveson
        </lastname>
        <forename>
         Kay
        </forename>
        <initials>
         K
        </initials>
        <identifier source="ORCID">
         http://orcid.org/0000-0003-4713-7306
        </identifier>
        <affiliationinfo>
         <affiliation>
          The Royal Free Hospital, London, UK.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Hansen
        </lastname>
        <forename>
         Richard
        </forename>
        <initials>
         R
        </initials>
        <identifier source="ORCID">
         http://orcid.org/0000-0002-3944-6646
        </identifier>
        <affiliationinfo>
         <affiliation>
          University of Glasgow, Glasgow, UK.
         </affiliation>
        </affiliationinfo>
        <affiliationinfo>
         <affiliation>
          Royal Hospital for Children, Glasgow, UK.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Hart
        </lastname>
        <forename>
         Ailsa
        </forename>
        <initials>
         A
        </initials>
        <identifier source="ORCID">
         http://orcid.org/0000-0002-7141-6076
        </identifier>
        <affiliationinfo>
         <affiliation>
          St Mark's Hospital, London, UK.
         </affiliation>
        </affiliationinfo>
        <affiliationinfo>
         <affiliation>
          Imperial College London, London, UK.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Hawthorne
        </lastname>
        <forename>
         A Barney
        </forename>
        <initials>
         AB
        </initials>
        <identifier source="ORCID">
         http://orcid.org/0000-0002-8768-4550
        </identifier>
        <affiliationinfo>
         <affiliation>
          University Hospital of Wales, Cardiff, UK.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Hayee
        </lastname>
        <forename>
         Bu'Hussain
        </forename>
        <initials>
         B
        </initials>
        <identifier source="ORCID">
         http://orcid.org/0000-0003-1670-8815
        </identifier>
        <affiliationinfo>
         <affiliation>
          King's College London, London, UK.
         </affiliation>
        </affiliationinfo>
        <affiliationinfo>
         <affiliation>
          King's College Hospital NHS Foundation Trust, London, UK.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Limdi
        </lastname>
        <forename>
         Jimmy K
        </forename>
        <initials>
         JK
        </initials>
        <identifier source="ORCID">
         http://orcid.org/0000-0002-1039-6251
        </identifier>
        <affiliationinfo>
         <affiliation>
          The Pennine Acute Hospitals NHS Trust, Manchester, UK.
         </affiliation>
        </affiliationinfo>
        <affiliationinfo>
         <affiliation>
          University of Manchester, Manchester, UK.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Murray
        </lastname>
        <forename>
         Charles D
        </forename>
        <initials>
         CD
        </initials>
        <identifier source="ORCID">
         http://orcid.org/0000-0001-6736-1546
        </identifier>
        <affiliationinfo>
         <affiliation>
          The Royal Free Hospital, London, UK.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Parkes
        </lastname>
        <forename>
         Gareth C
        </forename>
        <initials>
         GC
        </initials>
        <identifier source="ORCID">
         http://orcid.org/0000-0002-5285-7714
        </identifier>
        <affiliationinfo>
         <affiliation>
          Barts and the London School of Medicine and Dentistry, London, UK.
         </affiliation>
        </affiliationinfo>
        <affiliationinfo>
         <affiliation>
          The Royal London Hospital, Barts Health NHS Trust, London, UK.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Parkes
        </lastname>
        <forename>
         Miles
        </forename>
        <initials>
         M
        </initials>
        <identifier source="ORCID">
         http://orcid.org/0000-0002-6467-0631
        </identifier>
        <affiliationinfo>
         <affiliation>
          Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Patel
        </lastname>
        <forename>
         Kamal
        </forename>
        <initials>
         K
        </initials>
        <affiliationinfo>
         <affiliation>
          St George's University Hospitals NHS Foundation Trust, London, UK.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Pollok
        </lastname>
        <forename>
         Richard C
        </forename>
        <initials>
         RC
        </initials>
        <identifier source="ORCID">
         http://orcid.org/0000-0001-6452-6763
        </identifier>
        <affiliationinfo>
         <affiliation>
          St George's University Hospitals NHS Foundation Trust, London, UK.
         </affiliation>
        </affiliationinfo>
        <affiliationinfo>
         <affiliation>
          St George's, University of London, London, UK.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Powell
        </lastname>
        <forename>
         Nick
        </forename>
        <initials>
         N
        </initials>
        <identifier source="ORCID">
         http://orcid.org/0000-0003-3231-6950
        </identifier>
        <affiliationinfo>
         <affiliation>
          Imperial College London, London, UK.
         </affiliation>
        </affiliationinfo>
        <affiliationinfo>
         <affiliation>
          Imperial College Healthcare NHS Trust, London, UK.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Probert
        </lastname>
        <forename>
         Chris S
        </forename>
        <initials>
         CS
        </initials>
        <identifier source="ORCID">
         http://orcid.org/0000-0003-0477-6714
        </identifier>
        <affiliationinfo>
         <affiliation>
          Liverpool University Hospitals NHS Foundation Trusts, Liverpool, UK.
         </affiliation>
        </affiliationinfo>
        <affiliationinfo>
         <affiliation>
          University of Liverpool, Liverpool, UK.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Raine
        </lastname>
        <forename>
         Tim
        </forename>
        <initials>
         T
        </initials>
        <identifier source="ORCID">
         http://orcid.org/0000-0002-5855-9873
        </identifier>
        <affiliationinfo>
         <affiliation>
          Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Sebastian
        </lastname>
        <forename>
         Shaji
        </forename>
        <initials>
         S
        </initials>
        <identifier source="ORCID">
         http://orcid.org/0000-0002-3670-6545
        </identifier>
        <affiliationinfo>
         <affiliation>
          Hull University Teaching Hospitals NHS Trust, Hull, UK.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Selinger
        </lastname>
        <forename>
         Christian
        </forename>
        <initials>
         C
        </initials>
        <identifier source="ORCID">
         http://orcid.org/0000-0003-2022-5859
        </identifier>
        <affiliationinfo>
         <affiliation>
          Leeds Teaching Hospitals NHS Trust, Leeds, UK.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Smith
        </lastname>
        <forename>
         Philip J
        </forename>
        <initials>
         PJ
        </initials>
        <identifier source="ORCID">
         http://orcid.org/0000-0003-1568-3978
        </identifier>
        <affiliationinfo>
         <affiliation>
          Liverpool University Hospitals NHS Foundation Trusts, Liverpool, UK.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Stansfield
        </lastname>
        <forename>
         Catherine
        </forename>
        <initials>
         C
        </initials>
        <identifier source="ORCID">
         http://orcid.org/0000-0002-7775-2337
        </identifier>
        <affiliationinfo>
         <affiliation>
          Salford Royal NHS Foundation Trust, Salford, UK.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Younge
        </lastname>
        <forename>
         Lisa
        </forename>
        <initials>
         L
        </initials>
        <identifier source="ORCID">
         http://orcid.org/0000-0002-3436-9696
        </identifier>
        <affiliationinfo>
         <affiliation>
          Crohn's and Colitis UK, St Albans, Hertfordshire, UK.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Lindsay
        </lastname>
        <forename>
         James O
        </forename>
        <initials>
         JO
        </initials>
        <identifier source="ORCID">
         http://orcid.org/0000-0003-3353-9590
        </identifier>
        <affiliationinfo>
         <affiliation>
          Barts and the London School of Medicine and Dentistry, London, UK.
         </affiliation>
        </affiliationinfo>
        <affiliationinfo>
         <affiliation>
          The Royal London Hospital, Barts Health NHS Trust, London, UK.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Irving
        </lastname>
        <forename>
         Peter M
        </forename>
        <initials>
         PM
        </initials>
        <identifier source="ORCID">
         http://orcid.org/0000-0003-0972-8148
        </identifier>
        <affiliationinfo>
         <affiliation>
          King's College London, London, UK.
         </affiliation>
        </affiliationinfo>
        <affiliationinfo>
         <affiliation>
          Guy's and St Thomas' NHS Foundation Trust, London, UK.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Lees
        </lastname>
        <forename>
         Charlie W
        </forename>
        <initials>
         CW
        </initials>
        <identifier source="ORCID">
         http://orcid.org/0000-0002-0732-8215
        </identifier>
        <affiliationinfo>
         <affiliation>
          University of Edinburgh, Edinburgh, UK charlie.lees@ed.ac.uk.
         </affiliation>
        </affiliationinfo>
        <affiliationinfo>
         <affiliation>
          Western General Hospital, Edinburgh, UK.
         </affiliation>
        </affiliationinfo>
       </author>
      </authorlist>
      <language>
       eng
      </language>
      <publicationtypelist>
       <publicationtype ui="D016428">
        Journal Article
       </publicationtype>
      </publicationtypelist>
      <articledate datetype="Electronic">
       <year>
        2020
       </year>
       <month>
        04
       </month>
       <day>
        17
       </day>
      </articledate>
     </article>
     <medlinejournalinfo>
      <country>
       England
      </country>
      <medlineta>
       Gut
      </medlineta>
      <nlmuniqueid>
       2985108R
      </nlmuniqueid>
      <issnlinking>
       0017-5749
      </issnlinking>
     </medlinejournalinfo>
     <citationsubset>
      AIM
     </citationsubset>
     <citationsubset>
      IM
     </citationsubset>
     <keywordlist owner="NOTNLM">
      <keyword majortopicyn="N">
       crohn's colitis
      </keyword>
      <keyword majortopicyn="N">
       crohn's disease
      </keyword>
      <keyword majortopicyn="N">
       ulcerative colitis
      </keyword>
     </keywordlist>
     <coistatement>
      Competing interests: For details of conflicts of interest see online supplementary table 1.
     </coistatement>
    </medlinecitation>
    <pubmeddata>
     <history>
      <pubmedpubdate pubstatus="received">
       <year>
        2020
       </year>
       <month>
        03
       </month>
       <day>
        28
       </day>
      </pubmedpubdate>
      <pubmedpubdate pubstatus="revised">
       <year>
        2020
       </year>
       <month>
        04
       </month>
       <day>
        03
       </day>
      </pubmedpubdate>
      <pubmedpubdate pubstatus="accepted">
       <year>
        2020
       </year>
       <month>
        04
       </month>
       <day>
        06
       </day>
      </pubmedpubdate>
      <pubmedpubdate pubstatus="entrez">
       <year>
        2020
       </year>
       <month>
        4
       </month>
       <day>
        19
       </day>
       <hour>
        6
       </hour>
       <minute>
        0
       </minute>
      </pubmedpubdate>
      <pubmedpubdate pubstatus="pubmed">
       <year>
        2020
       </year>
       <month>
        4
       </month>
       <day>
        19
       </day>
       <hour>
        6
       </hour>
       <minute>
        0
       </minute>
      </pubmedpubdate>
      <pubmedpubdate pubstatus="medline">
       <year>
        2020
       </year>
       <month>
        4
       </month>
       <day>
        19
       </day>
       <hour>
        6
       </hour>
       <minute>
        0
       </minute>
      </pubmedpubdate>
     </history>
     <publicationstatus>
      aheadofprint
     </publicationstatus>
     <articleidlist>
      <articleid idtype="pubmed">
       32303607
      </articleid>
      <articleid idtype="pii">
       gutjnl-2020-321244
      </articleid>
      <articleid idtype="doi">
       10.1136/gutjnl-2020-321244
      </articleid>
     </articleidlist>
    </pubmeddata>
   </pubmedarticle>
   <pubmedarticle>
    <medlinecitation owner="NLM" status="Publisher">
     <pmid version="1">
      32303365
     </pmid>
     <daterevised>
      <year>
       2020
      </year>
      <month>
       04
      </month>
      <day>
       18
      </day>
     </daterevised>
     <article pubmodel="Print-Electronic">
      <journal>
       <issn issntype="Electronic">
        2340-3284
       </issn>
       <journalissue citedmedium="Internet">
        <pubdate>
         <year>
          2020
         </year>
         <month>
          Apr
         </month>
         <day>
          14
         </day>
        </pubdate>
       </journalissue>
       <title>
        Revista espanola de anestesiologia y reanimacion
       </title>
       <isoabbreviation>
        Rev Esp Anestesiol Reanim
       </isoabbreviation>
      </journal>
      <articletitle>
       Two known therapies could be useful as adjuvant therapy in critical patients infected by COVID-19.
      </articletitle>
      <elocationid eidtype="pii" validyn="Y">
       S0034-9356(20)30075-X
      </elocationid>
      <elocationid eidtype="doi" validyn="Y">
       10.1016/j.redar.2020.03.004
      </elocationid>
      <abstract>
       <abstracttext>
        Pneumonia caused by coronavirus, which originated in Wuhan, China, in late 2019, has been spread around the world already becoming a pandemic. Unfortunately, there is not yet a specific vaccine or effective antiviral drug for treating COVID-19. Many of these patients deteriorate rapidly and require intubation and are mechanically ventilated, which is causing the collapse of the health system in many countries due to lack of ventilators and intensive care beds. In this document we review two simple adjuvant therapies to administer, without side effects, and low cost that could be useful for the treatment of acute severe coronavirus infection associated with acute respiratory syndrome (SARS-CoV-2). VitaminC, a potent antioxidant, has emerged as a relevant therapy due to its potential benefits when administered intravenous. The potential effect of vitaminC in reducing inflammation in the lungs could play a key role in lung injury caused by coronavirus infection. Another potential effective therapy is ozone: it has been extensively studied and used for many years and its effectiveness has been demonstrated so far in multiples studies. Nevertheless, our goal is not to make an exhaustive review of these therapies but spread the beneficial effects themselves. Obviously clinical trials are necessaries, but due to the potential benefit of these two therapies we highly recommended to add to the therapeutic arsenal.
       </abstracttext>
       <copyrightinformation>
        Copyright © 2020 Sociedad Española de Anestesiología, Reanimación y Terapéutica del Dolor. Publicado por Elsevier España, S.L.U. All rights reserved.
       </copyrightinformation>
      </abstract>
      <authorlist completeyn="Y">
       <author validyn="Y">
        <lastname>
         Hernández
        </lastname>
        <forename>
         A
        </forename>
        <initials>
         A
        </initials>
        <affiliationinfo>
         <affiliation>
          Director Anaesthesia &amp; ICU, Grupo Policlínica, Ibiza, Islas Baleares, España. Electronic address: albimar23@yahoo.es.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Papadakos
        </lastname>
        <forename>
         P J
        </forename>
        <initials>
         PJ
        </initials>
        <affiliationinfo>
         <affiliation>
          Director Critical Care Medicine, University of Rochester, Professor Anesthesia, Surgery, Neurology, and Neurosurgery, Rochester, Nueva York, Estados Unidos.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Torres
        </lastname>
        <forename>
         A
        </forename>
        <initials>
         A
        </initials>
        <affiliationinfo>
         <affiliation>
          Senior Consultant in Respiratory and Intensive Care Unit, Servei de Pneumologia, Hospital Clínic, Universitat de Barcelona. IDIBAPS, CIBERES, ICREA, Barcelona, España.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         González
        </lastname>
        <forename>
         D A
        </forename>
        <initials>
         DA
        </initials>
        <affiliationinfo>
         <affiliation>
          Consultant in Anaesthesia &amp; ICU, Clínica Universitaria de Navarra, Pamplona, España.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Vives
        </lastname>
        <forename>
         M
        </forename>
        <initials>
         M
        </initials>
        <affiliationinfo>
         <affiliation>
          Consultant in Anaesthesia &amp; ICU, Hospital Universitari Dr. Josep Trueta, Girona, España.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Ferrando
        </lastname>
        <forename>
         C
        </forename>
        <initials>
         C
        </initials>
        <affiliationinfo>
         <affiliation>
          Head of Surgical Intensive Care Unit, Hospital Clínic, Universitat de Barcelona. CIBERES, Barcelona, España.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Baeza
        </lastname>
        <forename>
         J
        </forename>
        <initials>
         J
        </initials>
        <affiliationinfo>
         <affiliation>
          Vice president World Federation of Ozone Therapy. Presidente de la Sociedad Española de Ozonoterapia. Profesor de Anatomía humana, Facultad de Medicina, Universidad de Valencia, Valencia, España.
         </affiliation>
        </affiliationinfo>
       </author>
      </authorlist>
      <language>
       eng
      </language>
      <language>
       spa
      </language>
      <publicationtypelist>
       <publicationtype ui="D016428">
        Journal Article
       </publicationtype>
      </publicationtypelist>
      <vernaculartitle>
       Dos terapias conocidas podrían ser efectivas como adyuvantes en el paciente crítico infectado por COVID-19.
      </vernaculartitle>
      <articledate datetype="Electronic">
       <year>
        2020
       </year>
       <month>
        04
       </month>
       <day>
        14
       </day>
      </articledate>
     </article>
     <medlinejournalinfo>
      <country>
       Spain
      </country>
      <medlineta>
       Rev Esp Anestesiol Reanim
      </medlineta>
      <nlmuniqueid>
       0134516
      </nlmuniqueid>
      <issnlinking>
       0034-9356
      </issnlinking>
     </medlinejournalinfo>
     <citationsubset>
      IM
     </citationsubset>
     <keywordlist owner="NOTNLM">
      <keyword majortopicyn="N">
       COVID-19
      </keyword>
      <keyword majortopicyn="N">
       Ozone
      </keyword>
      <keyword majortopicyn="N">
       Ozono
      </keyword>
      <keyword majortopicyn="N">
       SARS-CoV-2
      </keyword>
      <keyword majortopicyn="N">
       Vitamin C
      </keyword>
      <keyword majortopicyn="N">
       Vitamina C
      </keyword>
     </keywordlist>
    </medlinecitation>
    <pubmeddata>
     <history>
      <pubmedpubdate pubstatus="entrez">
       <year>
        2020
       </year>
       <month>
        4
       </month>
       <day>
        19
       </day>
       <hour>
        6
       </hour>
       <minute>
        0
       </minute>
      </pubmedpubdate>
      <pubmedpubdate pubstatus="pubmed">
       <year>
        2020
       </year>
       <month>
        4
       </month>
       <day>
        19
       </day>
       <hour>
        6
       </hour>
       <minute>
        0
       </minute>
      </pubmedpubdate>
      <pubmedpubdate pubstatus="medline">
       <year>
        2020
       </year>
       <month>
        4
       </month>
       <day>
        19
       </day>
       <hour>
        6
       </hour>
       <minute>
        0
       </minute>
      </pubmedpubdate>
     </history>
     <publicationstatus>
      aheadofprint
     </publicationstatus>
     <articleidlist>
      <articleid idtype="pubmed">
       32303365
      </articleid>
      <articleid idtype="pii">
       S0034-9356(20)30075-X
      </articleid>
      <articleid idtype="doi">
       10.1016/j.redar.2020.03.004
      </articleid>
     </articleidlist>
    </pubmeddata>
   </pubmedarticle>
   <pubmedarticle>
    <medlinecitation owner="NLM" status="Publisher">
     <pmid version="1">
      32302411
     </pmid>
     <daterevised>
      <year>
       2020
      </year>
      <month>
       04
      </month>
      <day>
       17
      </day>
     </daterevised>
     <article pubmodel="Print-Electronic">
      <journal>
       <issn issntype="Electronic">
        1532-6535
       </issn>
       <journalissue citedmedium="Internet">
        <pubdate>
         <year>
          2020
         </year>
         <month>
          Apr
         </month>
         <day>
          17
         </day>
        </pubdate>
       </journalissue>
       <title>
        Clinical pharmacology and therapeutics
       </title>
       <isoabbreviation>
        Clin. Pharmacol. Ther.
       </isoabbreviation>
      </journal>
      <articletitle>
       Clinical Pharmacology Perspectives on the Antiviral Activity of Azithromycin and Use in COVID-19.
      </articletitle>
      <elocationid eidtype="doi" validyn="Y">
       10.1002/cpt.1857
      </elocationid>
      <abstract>
       <abstracttext>
        Azithromycin (AZ) is a broad-spectrum macrolide antibiotic with a long half-life and a large volume of distribution. It is primarily used for the treatment of respiratory, enteric, and genitourinary bacterial infections. AZ is not approved for the treatment of viral infections, and there is no well-controlled, prospective, randomized clinical evidence to support AZ therapy in COVID-19 (Coronavirus Infectious Disease-2019). Nevertheless, there are anecdotal reports that some hospitals have begun to include AZ in combination with hydroxychloroquine (HCQ) or chloroquine (CQ) for treatment of COVID-19. It is essential that the clinical pharmacology (CP) characteristics of AZ be considered in planning and conducting clinical trials of AZ alone or in combination with other agents, to ensure safe study conduct and to increase the probability of achieving definitive answers regarding efficacy of AZ in the treatment of COVID-19. The safety profile of AZ used as an antibacterial agent is well-established.(1) This work assesses published in vitro and clinical evidence for AZ as an agent with antiviral properties. It also provides basic CP information relevant for planning and initiating COVID-19 clinical studies with AZ, summarizes safety data from healthy volunteer studies, and safety and efficacy from Phase 2 and Phase 2/3 studies in patients with uncomplicated malaria, including a Phase 2/3 study in pediatric patients following administration of AZ and CQ in combination. This paper may also serve to facilitate the consideration and use of a priori-defined control groups for future research.
       </abstracttext>
       <copyrightinformation>
        This article is protected by copyright. All rights reserved.
       </copyrightinformation>
      </abstract>
      <authorlist completeyn="Y">
       <author validyn="Y">
        <lastname>
         Damle
        </lastname>
        <forename>
         Bharat
        </forename>
        <initials>
         B
        </initials>
        <affiliationinfo>
         <affiliation>
          Pfizer Global Research and Development, New York, NY, 10017, USA.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Vourvahis
        </lastname>
        <forename>
         Manoli
        </forename>
        <initials>
         M
        </initials>
        <affiliationinfo>
         <affiliation>
          Pfizer Global Research and Development, New York, NY, 10017, USA.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Wang
        </lastname>
        <forename>
         Erjian
        </forename>
        <initials>
         E
        </initials>
        <affiliationinfo>
         <affiliation>
          Pfizer Global Research and Development, 10555 Science Center Dr, San Diego, CA, 92121, USA.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Leaney
        </lastname>
        <forename>
         Joanne
        </forename>
        <initials>
         J
        </initials>
        <affiliationinfo>
         <affiliation>
          Pfizer Global Research and Development, Sandwich, Kent, CT13 9NJ, UK.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Corrigan
        </lastname>
        <forename>
         Brian
        </forename>
        <initials>
         B
        </initials>
        <affiliationinfo>
         <affiliation>
          Pfizer Global Research and Development, 445 Eastern Point Road, Groton, CT, 06340, USA.
         </affiliation>
        </affiliationinfo>
       </author>
      </authorlist>
      <language>
       eng
      </language>
      <publicationtypelist>
       <publicationtype ui="D016428">
        Journal Article
       </publicationtype>
       <publicationtype ui="D016454">
        Review
       </publicationtype>
      </publicationtypelist>
      <articledate datetype="Electronic">
       <year>
        2020
       </year>
       <month>
        04
       </month>
       <day>
        17
       </day>
      </articledate>
     </article>
     <medlinejournalinfo>
      <country>
       United States
      </country>
      <medlineta>
       Clin Pharmacol Ther
      </medlineta>
      <nlmuniqueid>
       0372741
      </nlmuniqueid>
      <issnlinking>
       0009-9236
      </issnlinking>
     </medlinejournalinfo>
     <citationsubset>
      AIM
     </citationsubset>
     <citationsubset>
      IM
     </citationsubset>
     <keywordlist owner="NOTNLM">
      <keyword majortopicyn="N">
       Azithromycin
      </keyword>
      <keyword majortopicyn="N">
       COVID-19
      </keyword>
      <keyword majortopicyn="N">
       Chloroquine
      </keyword>
      <keyword majortopicyn="N">
       Coronavirus
      </keyword>
      <keyword majortopicyn="N">
       Hydroxychloroquine
      </keyword>
      <keyword majortopicyn="N">
       Pharmacokinetics
      </keyword>
      <keyword majortopicyn="N">
       SARS-CoV-2
      </keyword>
      <keyword majortopicyn="N">
       Safety
      </keyword>
     </keywordlist>
    </medlinecitation>
    <pubmeddata>
     <history>
      <pubmedpubdate pubstatus="entrez">
       <year>
        2020
       </year>
       <month>
        4
       </month>
       <day>
        18
       </day>
       <hour>
        6
       </hour>
       <minute>
        0
       </minute>
      </pubmedpubdate>
      <pubmedpubdate pubstatus="pubmed">
       <year>
        2020
       </year>
       <month>
        4
       </month>
       <day>
        18
       </day>
       <hour>
        6
       </hour>
       <minute>
        0
       </minute>
      </pubmedpubdate>
      <pubmedpubdate pubstatus="medline">
       <year>
        2020
       </year>
       <month>
        4
       </month>
       <day>
        18
       </day>
       <hour>
        6
       </hour>
       <minute>
        0
       </minute>
      </pubmedpubdate>
     </history>
     <publicationstatus>
      aheadofprint
     </publicationstatus>
     <articleidlist>
      <articleid idtype="pubmed">
       32302411
      </articleid>
      <articleid idtype="doi">
       10.1002/cpt.1857
      </articleid>
     </articleidlist>
    </pubmeddata>
   </pubmedarticle>
   <pubmedarticle>
    <medlinecitation owner="NLM" status="Publisher">
     <pmid version="1">
      32300516
     </pmid>
     <daterevised>
      <year>
       2020
      </year>
      <month>
       04
      </month>
      <day>
       17
      </day>
     </daterevised>
     <article pubmodel="Print-Electronic">
      <journal>
       <issn issntype="Print">
        2193-8210
       </issn>
       <journalissue citedmedium="Print">
        <pubdate>
         <year>
          2020
         </year>
         <month>
          Apr
         </month>
         <day>
          16
         </day>
        </pubdate>
       </journalissue>
       <title>
        Dermatology and therapy
       </title>
       <isoabbreviation>
        Dermatol Ther (Heidelb)
       </isoabbreviation>
      </journal>
      <articletitle>
       Novel Coronavirus Disease (COVID-19) and Biologic Therapy in Psoriasis: Infection Risk and Patient Counseling in Uncertain Times.
      </articletitle>
      <pagination>
       <medlinepgn>
        1-11
       </medlinepgn>
      </pagination>
      <elocationid eidtype="doi" validyn="Y">
       10.1007/s13555-020-00377-9
      </elocationid>
      <abstract>
       <abstracttext>
        With the emergence of the novel coronavirus disease (COVID-19) viral pandemic, there is uncertainty whether biologic agents for psoriasis may place patients at a higher risk for infection or more severe disease course. This commentary offers patient counseling recommendations based on the current available evidence. While there are currently no specific data for psoriasis biologics and COVID-19, data are presented here from phase III clinical trials of psoriasis biologics on rates of upper respiratory infection, influenza, and serious infection. Overall these data reveal that on the whole, psoriasis biologics do not show major increases in infection risk compared to placebo during the course of these trials. However, as the COVID-19 virus is a novel pathogen that is associated with mortality in a subset of patients, a cautious approach is warranted. We discuss factors that may alter the benefit-risk ratio of biologic use during this time of COVID-19 outbreak. Ultimately, treatment decisions should be made on the basis of dialogue between patient and provider, considering each patient's individualized situation. Once this pandemic has passed, it is only a matter of time before a new viral disease reignites the same issues discussed here.
       </abstracttext>
       <copyrightinformation>
        © The Author(s) 2020.
       </copyrightinformation>
      </abstract>
      <authorlist completeyn="Y">
       <author validyn="Y">
        <lastname>
         Brownstone
        </lastname>
        <forename>
         Nicholas D
        </forename>
        <initials>
         ND
        </initials>
        <affiliationinfo>
         <affiliation>
          Department of Dermatology, Psoriasis and Skin Treatment Center, University of California San Francisco, San Francisco, CA USA.
         </affiliation>
         <identifier source="GRID">
          grid.266102.1
         </identifier>
         <identifier source="ISNI">
          0000 0001 2297 6811
         </identifier>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Thibodeaux
        </lastname>
        <forename>
         Quinn G
        </forename>
        <initials>
         QG
        </initials>
        <affiliationinfo>
         <affiliation>
          Department of Dermatology, Psoriasis and Skin Treatment Center, University of California San Francisco, San Francisco, CA USA.
         </affiliation>
         <identifier source="GRID">
          grid.266102.1
         </identifier>
         <identifier source="ISNI">
          0000 0001 2297 6811
         </identifier>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Reddy
        </lastname>
        <forename>
         Vidhatha D
        </forename>
        <initials>
         VD
        </initials>
        <affiliationinfo>
         <affiliation>
          Department of Dermatology, Psoriasis and Skin Treatment Center, University of California San Francisco, San Francisco, CA USA.
         </affiliation>
         <identifier source="GRID">
          grid.266102.1
         </identifier>
         <identifier source="ISNI">
          0000 0001 2297 6811
         </identifier>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Myers
        </lastname>
        <forename>
         Bridget A
        </forename>
        <initials>
         BA
        </initials>
        <affiliationinfo>
         <affiliation>
          Department of Dermatology, Psoriasis and Skin Treatment Center, University of California San Francisco, San Francisco, CA USA.
         </affiliation>
         <identifier source="GRID">
          grid.266102.1
         </identifier>
         <identifier source="ISNI">
          0000 0001 2297 6811
         </identifier>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Chan
        </lastname>
        <forename>
         Stephanie Y
        </forename>
        <initials>
         SY
        </initials>
        <affiliationinfo>
         <affiliation>
          Department of Dermatology, Psoriasis and Skin Treatment Center, University of California San Francisco, San Francisco, CA USA.
         </affiliation>
         <identifier source="GRID">
          grid.266102.1
         </identifier>
         <identifier source="ISNI">
          0000 0001 2297 6811
         </identifier>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Bhutani
        </lastname>
        <forename>
         Tina
        </forename>
        <initials>
         T
        </initials>
        <affiliationinfo>
         <affiliation>
          Department of Dermatology, Psoriasis and Skin Treatment Center, University of California San Francisco, San Francisco, CA USA.
         </affiliation>
         <identifier source="GRID">
          grid.266102.1
         </identifier>
         <identifier source="ISNI">
          0000 0001 2297 6811
         </identifier>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Liao
        </lastname>
        <forename>
         Wilson
        </forename>
        <initials>
         W
        </initials>
        <affiliationinfo>
         <affiliation>
          Department of Dermatology, Psoriasis and Skin Treatment Center, University of California San Francisco, San Francisco, CA USA.
         </affiliation>
         <identifier source="GRID">
          grid.266102.1
         </identifier>
         <identifier source="ISNI">
          0000 0001 2297 6811
         </identifier>
        </affiliationinfo>
       </author>
      </authorlist>
      <language>
       eng
      </language>
      <databanklist completeyn="Y">
       <databank>
        <databankname>
         figshare
        </databankname>
        <accessionnumberlist>
         <accessionnumber>
          10.6084/m9.figshare.12063624
         </accessionnumber>
        </accessionnumberlist>
       </databank>
      </databanklist>
      <publicationtypelist>
       <publicationtype ui="D016428">
        Journal Article
       </publicationtype>
      </publicationtypelist>
      <articledate datetype="Electronic">
       <year>
        2020
       </year>
       <month>
        04
       </month>
       <day>
        16
       </day>
      </articledate>
     </article>
     <medlinejournalinfo>
      <country>
       Switzerland
      </country>
      <medlineta>
       Dermatol Ther (Heidelb)
      </medlineta>
      <nlmuniqueid>
       101590450
      </nlmuniqueid>
     </medlinejournalinfo>
     <keywordlist owner="NOTNLM">
      <keyword majortopicyn="N">
       Biologics
      </keyword>
      <keyword majortopicyn="N">
       COVID-19
      </keyword>
      <keyword majortopicyn="N">
       Coronavirus
      </keyword>
      <keyword majortopicyn="N">
       Infection
      </keyword>
      <keyword majortopicyn="N">
       Pandemic
      </keyword>
      <keyword majortopicyn="N">
       Psoriasis
      </keyword>
      <keyword majortopicyn="N">
       SARS-CoV-2
      </keyword>
     </keywordlist>
    </medlinecitation>
    <pubmeddata>
     <history>
      <pubmedpubdate pubstatus="received">
       <year>
        2020
       </year>
       <month>
        03
       </month>
       <day>
        25
       </day>
      </pubmedpubdate>
      <pubmedpubdate pubstatus="entrez">
       <year>
        2020
       </year>
       <month>
        4
       </month>
       <day>
        18
       </day>
       <hour>
        6
       </hour>
       <minute>
        0
       </minute>
      </pubmedpubdate>
      <pubmedpubdate pubstatus="pubmed">
       <year>
        2020
       </year>
       <month>
        4
       </month>
       <day>
        18
       </day>
       <hour>
        6
       </hour>
       <minute>
        0
       </minute>
      </pubmedpubdate>
      <pubmedpubdate pubstatus="medline">
       <year>
        2020
       </year>
       <month>
        4
       </month>
       <day>
        18
       </day>
       <hour>
        6
       </hour>
       <minute>
        0
       </minute>
      </pubmedpubdate>
     </history>
     <publicationstatus>
      aheadofprint
     </publicationstatus>
     <articleidlist>
      <articleid idtype="pubmed">
       32300516
      </articleid>
      <articleid idtype="doi">
       10.1007/s13555-020-00377-9
      </articleid>
      <articleid idtype="pii">
       377
      </articleid>
      <articleid idtype="pmc">
       PMC7160052
      </articleid>
     </articleidlist>
     <?pmcsd ?>
    </pubmeddata>
   </pubmedarticle>
   <pubmedarticle>
    <medlinecitation owner="NLM" status="Publisher">
     <pmid version="1">
      32298807
     </pmid>
     <daterevised>
      <year>
       2020
      </year>
      <month>
       04
      </month>
      <day>
       18
      </day>
     </daterevised>
     <article pubmodel="Print-Electronic">
      <journal>
       <issn issntype="Electronic">
        1523-6536
       </issn>
       <journalissue citedmedium="Internet">
        <pubdate>
         <year>
          2020
         </year>
         <month>
          Apr
         </month>
         <day>
          13
         </day>
        </pubdate>
       </journalissue>
       <title>
        Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation
       </title>
       <isoabbreviation>
        Biol. Blood Marrow Transplant.
       </isoabbreviation>
      </journal>
      <articletitle>
       CAR T Cell Therapy During the COVID-19 Pandemic.
      </articletitle>
      <elocationid eidtype="pii" validyn="Y">
       S1083-8791(20)30217-2
      </elocationid>
      <elocationid eidtype="doi" validyn="Y">
       10.1016/j.bbmt.2020.04.008
      </elocationid>
      <abstract>
       <abstracttext>
        The COVID-19 pandemic has significantly impacted the delivery of cellular therapeutics, including chimeric antigen receptor (CAR) T cells. This impact has extended beyond patient care to include logistics, administration, and distribution of increasingly limited health care resources. Based on the collective experience of the CAR T-cell Consortium investigators, we review and address several questions and concerns regarding cellular therapy administration in the setting of COVID-19 and make general recommendations to address these issues. Specifically we address: 1) necessary resources for safe administration of cell therapies; 2) determinants of cell therapy utilization; 3) selection among patients with B-cell non-Hodgkin lymphomas and 4) B-cell acute lymphocytic leukemia; 5) supportive measures during cell therapy administration; 6) use and prioritization of tocilizumab, and 7) collaborative care with referring physicians. These recommendations were carefully formulated with the understanding that resources allocation is of the utmost importance and the decision to proceed with CAR T cell therapy will require extensive discussion of potential risks and benefits. Though these recommendations are fluid, at this time it is our opinion that the COVID-19 pandemic should not serve as reason to defer CAR T cell therapy for patients truly in need of a potentially curative therapy.
       </abstracttext>
       <copyrightinformation>
        Copyright © 2020 Elsevier Ltd. All rights reserved.
       </copyrightinformation>
      </abstract>
      <authorlist completeyn="Y">
       <author validyn="Y">
        <lastname>
         Bachanova
        </lastname>
        <forename>
         Veronika
        </forename>
        <initials>
         V
        </initials>
        <affiliationinfo>
         <affiliation>
          University of Minnesota, Minneapolis, MN.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Bishop
        </lastname>
        <forename>
         Michael R
        </forename>
        <initials>
         MR
        </initials>
        <affiliationinfo>
         <affiliation>
          Hematopoietic Cellular Therapy Program, Section of Hematology/Oncology, Department of Medicine, University of Chicago, Chicago, IL.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Dahi
        </lastname>
        <forename>
         Parastoo
        </forename>
        <initials>
         P
        </initials>
        <affiliationinfo>
         <affiliation>
          Adult Bone Marrow Transplant Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY; Department of Medicine, Weill Cornell Medical College, New York, NY.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Dholaria
        </lastname>
        <forename>
         Bhagirathbhai
        </forename>
        <initials>
         B
        </initials>
        <affiliationinfo>
         <affiliation>
          Vanderbilt-Ingram Cancer Center, Nashville, TN.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Grupp
        </lastname>
        <forename>
         Stephan A
        </forename>
        <initials>
         SA
        </initials>
        <affiliationinfo>
         <affiliation>
          Children's Hospital of Philadelphia, Philadelphia, PA.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Hayes-Lattin
        </lastname>
        <forename>
         Brandon
        </forename>
        <initials>
         B
        </initials>
        <affiliationinfo>
         <affiliation>
          Knight Cancer Institute, Oregon Health &amp; Science University, Portland, OR.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Janakiram
        </lastname>
        <forename>
         Murali
        </forename>
        <initials>
         M
        </initials>
        <affiliationinfo>
         <affiliation>
          University of Minnesota, Minneapolis, MN.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Maziarz
        </lastname>
        <forename>
         Richard T
        </forename>
        <initials>
         RT
        </initials>
        <affiliationinfo>
         <affiliation>
          Knight Cancer Institute, Oregon Health &amp; Science University, Portland, OR.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         McGuirk
        </lastname>
        <forename>
         Joseph P
        </forename>
        <initials>
         JP
        </initials>
        <affiliationinfo>
         <affiliation>
          University of Kansas Cancer Center, Westwood, KS.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Nastoupil
        </lastname>
        <forename>
         Loretta J
        </forename>
        <initials>
         LJ
        </initials>
        <affiliationinfo>
         <affiliation>
          The University of Texas MD Anderson Cancer Center, Houston, TX.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Oluwole
        </lastname>
        <forename>
         Olalekan O
        </forename>
        <initials>
         OO
        </initials>
        <affiliationinfo>
         <affiliation>
          Vanderbilt-Ingram Cancer Center, Nashville, TN.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Perales
        </lastname>
        <forename>
         Miguel-Angel
        </forename>
        <initials>
         MA
        </initials>
        <affiliationinfo>
         <affiliation>
          Adult Bone Marrow Transplant Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY; Department of Medicine, Weill Cornell Medical College, New York, NY.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Porter
        </lastname>
        <forename>
         David L
        </forename>
        <initials>
         DL
        </initials>
        <affiliationinfo>
         <affiliation>
          University of Pennsylvania and Abramson Cancer Center, Philadelphia, PA. Electronic address: david.porter@pennmedicine.upenn.edu.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Riedell
        </lastname>
        <forename>
         Peter A
        </forename>
        <initials>
         PA
        </initials>
        <affiliationinfo>
         <affiliation>
          Hematopoietic Cellular Therapy Program, Section of Hematology/Oncology, Department of Medicine, University of Chicago, Chicago, IL. Electronic address: priedell@medicine.bsd.uchicago.edu.
         </affiliation>
        </affiliationinfo>
       </author>
      </authorlist>
      <language>
       eng
      </language>
      <publicationtypelist>
       <publicationtype ui="D016428">
        Journal Article
       </publicationtype>
       <publicationtype ui="D016454">
        Review
       </publicationtype>
      </publicationtypelist>
      <articledate datetype="Electronic">
       <year>
        2020
       </year>
       <month>
        04
       </month>
       <day>
        13
       </day>
      </articledate>
     </article>
     <medlinejournalinfo>
      <country>
       United States
      </country>
      <medlineta>
       Biol Blood Marrow Transplant
      </medlineta>
      <nlmuniqueid>
       9600628
      </nlmuniqueid>
      <issnlinking>
       1083-8791
      </issnlinking>
     </medlinejournalinfo>
     <citationsubset>
      IM
     </citationsubset>
     <keywordlist owner="NOTNLM">
      <keyword majortopicyn="N">
       COVID-19
      </keyword>
      <keyword majortopicyn="N">
       Cellular therapy
      </keyword>
      <keyword majortopicyn="N">
       Chimeric antigen receptor T-cells
      </keyword>
      <keyword majortopicyn="N">
       Coronavirus
      </keyword>
      <keyword majortopicyn="N">
       Pandemic
      </keyword>
     </keywordlist>
     <coistatement>
      Declaration of competing interest VB: Research funding from Novartis, Celgene, Incyte, Gamida Cell, and GT Biopharma; advisory board for Kite/Gilead and Seattle Genetics. MRB: Consultant and/or advisor for Celgene Corporation; Kite Pharma, Inc./Gilead; CRISPR Therapeutics, and Novartis Pharmaceuticals Corporation. Speakers Bureau for Kite Pharma, Inc./Gilead, BMS, and Celgene. Other financial interest/relationship for Novartis Pharmaceuticals Corporation as a part of steering committees. PD: Advisory board for Kite/Gilead. BD: Consultant and/or advisor for Celgene. Institutional research support from Angiocrine, Celyed, and Poseida therapeutics. SAG: CBMG: Consultancy; Novartis: Research Funding; Kite: Research Funding; Servier: Research Funding; Novartis: Consultancy, Research Funding; Roche: Consultancy; GSK: Consultancy; Cure Genetics: Consultancy; Humanigen: Consultancy; Jazz: Other: study steering committees or scientific advisory boards; Adaptimmune: Other: study steering committees or scientific advisory boards. BHL and MJ: report no COIs. RTM: Honoraria/ consultancy fees from Bristol-Myers Squibb/JUNO, CRISPR Therapeutics, Gilead/ Kite Therapeutics, Incyte, Intellia Therapeutics, Kadmon, Omeros, and PACT Pharma. He serves on a Scientific Board for Artiva Biotherapeutics. He has served on DSMBs for Novartis and Athersys, Inc. He served as Chair of Scientific Steering Committee for the phase II tisagenlecleucel study sponsored by Novartis Pharmaceuticals Corporation. He also has patents from Athersys, Inc. Re: work with Athersys and Novartis, as an OHSU employee, these potential conflicts of interest have been reviewed and are managed by OHSU. JPM: Research/grant support from Novartis, Fresenius Biotech, Astellas, Bellicum Pharmaceuticals, Gamida cell, Pluristem Ltd; advisory board, speaker's bureau, travel accommodations and expenses and research funding from Kite/Gilead; manuscript assistance from ArticulateScience LLC; he serves on the advisory board, receives travel accommodations and expenses along with research funding support from grant support Bristol-Myers Squibb/JUNO; he receives honoraria, travel expenses along with grant/research funding from AlloVir. LJN: Honorarium from Bayer, Celgene, Gamida Cell, Genentech, KITE/Gilead, Novartis, MEI, TG Therapeutics along with research support from Celgene, Genentech, Karus Therapeutics, Merck, Novartis, and TG Therapeutics. OOO: Scientific advisory board for Pfizer, Spectrum, Bayer and Kite/Gilead. Honoraria from Pfizer. MAP: Honoraria from AbbVie, Bellicum, Bristol-Myers Squibb, Incyte, Merck, Novartis, Nektar Therapeutics, Omeros, and Takeda. He serves on DSMBs for Servier and Medigene, and the scientific advisory boards of MolMed and NexImmune. He has received research support for clinical trials from Incyte, Kite/Gilead and Miltenyi Biotec. DLP: Employment: Genentech, Roche (Spouse employment); Stock and Other Ownership Interests: Genentech, Roche (Spouse employment); Consulting or Advisory Role: Novartis, Kite/Gilead, Incyte, Gerson Lehrman Group, Glenmark, Janssen; Research Funding: Novartis; Patents, Royalties, Other Intellectual Property: Dr. Porter is a patent inventor for CTL019. Travel, Accommodations, Expenses: Kite Pharma, Novartis; Other Relationship: National Marrow Donor Program (Board of Directors), American Board of Internal Medicine (Board exam writing committee member). PAR: Speaker for Kite Pharma, Bayer, and advisory board for Verastem, Novartis, Celgene/BMS, and Bayer. Honoraria from Novartis and institutional research support from Celgene/BMS, Kite Pharma, and Novartis. MAP: research support from Novartis. OOO: research support from Novartis. RTM: research support from Novartis.
     </coistatement>
    </medlinecitation>
    <pubmeddata>
     <history>
      <pubmedpubdate pubstatus="received">
       <year>
        2020
       </year>
       <month>
        04
       </month>
       <day>
        06
       </day>
      </pubmedpubdate>
      <pubmedpubdate pubstatus="accepted">
       <year>
        2020
       </year>
       <month>
        04
       </month>
       <day>
        06
       </day>
      </pubmedpubdate>
      <pubmedpubdate pubstatus="entrez">
       <year>
        2020
       </year>
       <month>
        4
       </month>
       <day>
        17
       </day>
       <hour>
        6
       </hour>
       <minute>
        0
       </minute>
      </pubmedpubdate>
      <pubmedpubdate pubstatus="pubmed">
       <year>
        2020
       </year>
       <month>
        4
       </month>
       <day>
        17
       </day>
       <hour>
        6
       </hour>
       <minute>
        0
       </minute>
      </pubmedpubdate>
      <pubmedpubdate pubstatus="medline">
       <year>
        2020
       </year>
       <month>
        4
       </month>
       <day>
        17
       </day>
       <hour>
        6
       </hour>
       <minute>
        0
       </minute>
      </pubmedpubdate>
     </history>
     <publicationstatus>
      aheadofprint
     </publicationstatus>
     <articleidlist>
      <articleid idtype="pubmed">
       32298807
      </articleid>
      <articleid idtype="pii">
       S1083-8791(20)30217-2
      </articleid>
      <articleid idtype="doi">
       10.1016/j.bbmt.2020.04.008
      </articleid>
      <articleid idtype="pmc">
       PMC7162777
      </articleid>
     </articleidlist>
    </pubmeddata>
   </pubmedarticle>
   <pubmedarticle>
    <medlinecitation owner="NLM" status="Publisher">
     <pmid version="1">
      32297223
     </pmid>
     <daterevised>
      <year>
       2020
      </year>
      <month>
       04
      </month>
      <day>
       16
      </day>
     </daterevised>
     <article pubmodel="Print-Electronic">
      <journal>
       <issn issntype="Print">
        2193-8210
       </issn>
       <journalissue citedmedium="Print">
        <pubdate>
         <year>
          2020
         </year>
         <month>
          Apr
         </month>
         <day>
          16
         </day>
        </pubdate>
       </journalissue>
       <title>
        Dermatology and therapy
       </title>
       <isoabbreviation>
        Dermatol Ther (Heidelb)
       </isoabbreviation>
      </journal>
      <articletitle>
       Novel Coronavirus Disease (COVID-19) and Biologic Therapy in Psoriasis: Infection Risk and Patient Counseling in Uncertain Times.
      </articletitle>
      <elocationid eidtype="doi" validyn="Y">
       10.1007/s13555-020-00377-9
      </elocationid>
      <abstract>
       <abstracttext>
        With the emergence of the novel coronavirus disease (COVID-19) viral pandemic, there is uncertainty whether biologic agents for psoriasis may place patients at a higher risk for infection or more severe disease course. This commentary offers patient counseling recommendations based on the current available evidence. While there are currently no specific data for psoriasis biologics and COVID-19, data are presented here from phase III clinical trials of psoriasis biologics on rates of upper respiratory infection, influenza, and serious infection. Overall these data reveal that on the whole, psoriasis biologics do not show major increases in infection risk compared to placebo during the course of these trials. However, as the COVID-19 virus is a novel pathogen that is associated with mortality in a subset of patients, a cautious approach is warranted. We discuss factors that may alter the benefit-risk ratio of biologic use during this time of COVID-19 outbreak. Ultimately, treatment decisions should be made on the basis of dialogue between patient and provider, considering each patient's individualized situation. Once this pandemic has passed, it is only a matter of time before a new viral disease reignites the same issues discussed here.
       </abstracttext>
      </abstract>
      <authorlist completeyn="Y">
       <author validyn="Y">
        <lastname>
         Brownstone
        </lastname>
        <forename>
         Nicholas D
        </forename>
        <initials>
         ND
        </initials>
        <affiliationinfo>
         <affiliation>
          Department of Dermatology, Psoriasis and Skin Treatment Center, University of California San Francisco, San Francisco, CA, USA.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Thibodeaux
        </lastname>
        <forename>
         Quinn G
        </forename>
        <initials>
         QG
        </initials>
        <affiliationinfo>
         <affiliation>
          Department of Dermatology, Psoriasis and Skin Treatment Center, University of California San Francisco, San Francisco, CA, USA.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Reddy
        </lastname>
        <forename>
         Vidhatha D
        </forename>
        <initials>
         VD
        </initials>
        <affiliationinfo>
         <affiliation>
          Department of Dermatology, Psoriasis and Skin Treatment Center, University of California San Francisco, San Francisco, CA, USA.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Myers
        </lastname>
        <forename>
         Bridget A
        </forename>
        <initials>
         BA
        </initials>
        <affiliationinfo>
         <affiliation>
          Department of Dermatology, Psoriasis and Skin Treatment Center, University of California San Francisco, San Francisco, CA, USA.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Chan
        </lastname>
        <forename>
         Stephanie Y
        </forename>
        <initials>
         SY
        </initials>
        <affiliationinfo>
         <affiliation>
          Department of Dermatology, Psoriasis and Skin Treatment Center, University of California San Francisco, San Francisco, CA, USA.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Bhutani
        </lastname>
        <forename>
         Tina
        </forename>
        <initials>
         T
        </initials>
        <affiliationinfo>
         <affiliation>
          Department of Dermatology, Psoriasis and Skin Treatment Center, University of California San Francisco, San Francisco, CA, USA.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Liao
        </lastname>
        <forename>
         Wilson
        </forename>
        <initials>
         W
        </initials>
        <affiliationinfo>
         <affiliation>
          Department of Dermatology, Psoriasis and Skin Treatment Center, University of California San Francisco, San Francisco, CA, USA. wilson.liao@ucsf.edu.
         </affiliation>
        </affiliationinfo>
       </author>
      </authorlist>
      <language>
       eng
      </language>
      <publicationtypelist>
       <publicationtype ui="D016422">
        Letter
       </publicationtype>
      </publicationtypelist>
      <articledate datetype="Electronic">
       <year>
        2020
       </year>
       <month>
        04
       </month>
       <day>
        16
       </day>
      </articledate>
     </article>
     <medlinejournalinfo>
      <country>
       Switzerland
      </country>
      <medlineta>
       Dermatol Ther (Heidelb)
      </medlineta>
      <nlmuniqueid>
       101590450
      </nlmuniqueid>
     </medlinejournalinfo>
     <keywordlist owner="NOTNLM">
      <keyword majortopicyn="N">
       Biologics
      </keyword>
      <keyword majortopicyn="N">
       COVID-19
      </keyword>
      <keyword majortopicyn="N">
       Coronavirus
      </keyword>
      <keyword majortopicyn="N">
       Infection
      </keyword>
      <keyword majortopicyn="N">
       Pandemic
      </keyword>
      <keyword majortopicyn="N">
       Psoriasis
      </keyword>
      <keyword majortopicyn="N">
       SARS-CoV-2
      </keyword>
     </keywordlist>
    </medlinecitation>
    <pubmeddata>
     <history>
      <pubmedpubdate pubstatus="received">
       <year>
        2020
       </year>
       <month>
        03
       </month>
       <day>
        25
       </day>
      </pubmedpubdate>
      <pubmedpubdate pubstatus="entrez">
       <year>
        2020
       </year>
       <month>
        4
       </month>
       <day>
        17
       </day>
       <hour>
        6
       </hour>
       <minute>
        0
       </minute>
      </pubmedpubdate>
      <pubmedpubdate pubstatus="pubmed">
       <year>
        2020
       </year>
       <month>
        4
       </month>
       <day>
        17
       </day>
       <hour>
        6
       </hour>
       <minute>
        0
       </minute>
      </pubmedpubdate>
      <pubmedpubdate pubstatus="medline">
       <year>
        2020
       </year>
       <month>
        4
       </month>
       <day>
        17
       </day>
       <hour>
        6
       </hour>
       <minute>
        0
       </minute>
      </pubmedpubdate>
     </history>
     <publicationstatus>
      aheadofprint
     </publicationstatus>
     <articleidlist>
      <articleid idtype="pubmed">
       32297223
      </articleid>
      <articleid idtype="doi">
       10.1007/s13555-020-00377-9
      </articleid>
      <articleid idtype="pii">
       10.1007/s13555-020-00377-9
      </articleid>
     </articleidlist>
    </pubmeddata>
   </pubmedarticle>
   <pubmedarticle>
    <medlinecitation owner="NLM" status="In-Process">
     <pmid version="1">
      32293807
     </pmid>
     <daterevised>
      <year>
       2020
      </year>
      <month>
       04
      </month>
      <day>
       17
      </day>
     </daterevised>
     <article pubmodel="Print">
      <journal>
       <issn issntype="Electronic">
        1758-2652
       </issn>
       <journalissue citedmedium="Internet">
        <volume>
         23
        </volume>
        <issue>
         4
        </issue>
        <pubdate>
         <year>
          2020
         </year>
         <month>
          04
         </month>
        </pubdate>
       </journalissue>
       <title>
        Journal of the International AIDS Society
       </title>
       <isoabbreviation>
        J Int AIDS Soc
       </isoabbreviation>
      </journal>
      <articletitle>
       Systematic review of the efficacy and safety of antiretroviral drugs against SARS, MERS or COVID-19: initial assessment.
      </articletitle>
      <pagination>
       <medlinepgn>
        e25489
       </medlinepgn>
      </pagination>
      <elocationid eidtype="doi" validyn="Y">
       10.1002/jia2.25489
      </elocationid>
      <abstract>
       <abstracttext label="INTRODUCTION">
        Several antiretroviral drugs are being considered for the treatment of COVID-19, the disease caused by a newly identified coronavirus, (SARS-CoV-2). We systematically reviewed the clinical outcomes of using antiretroviral drugs for the prevention and treatment of coronaviruses and planned clinical trials.
       </abstracttext>
       <abstracttext label="METHODS">
        Three databases were screened from inception to 30 March 2020 for studies reporting clinical outcomes of patients with SARS, MERS or COVID-19 treated with antiretrovirals.
       </abstracttext>
       <abstracttext label="RESULTS">
        From an initial screen of 433 titles, two randomized trials and 24 observational studies provided clinical outcome data on the use of antiretroviral drugs; most studies reported outcomes using LPV/r as treatment. Of the 21 observational studies reporting treatment outcomes, there were three studies among patients with SARS, six studies among patients with MERS and 12 studies among patients with COVID-19. In one randomized trial 99 patients with severe COVID-19 illness were randomized to receive LPV/r (400/100 mg twice a day) and 100 patients to standard of care for 14 days: LPV/r was not associated with a statistically significant difference in time to clinical improvement, although LPV/r given within 12 days of symptoms was associated with shorter time to clinical improvement; 28 day mortality was numerically lower in the LPV/r group (14/99) compared to the control group (25/100), but this difference was not statistically significant. The second trial found no benefit. The certainty of the evidence for the randomized trials was low. In the observational studies 3 out of 361 patients who received LPV/r died; the certainty of evidence was very low. Three studies reported a possible protective effect of LPV/r as post-exposure prophylaxis. Again, the certainty of the evidence was very low due to uncertainty due to limited sample size.
       </abstracttext>
       <abstracttext label="CONCLUSIONS">
        On the basis of the available evidence it is uncertain whether LPV/r and other antiretrovirals improve clinical outcomes or prevent infection among patients at high risk of acquiring COVID-19.
       </abstracttext>
       <copyrightinformation>
        © 2020 World Health Organization; licensed by by John Wiley &amp; Sons Ltd on behalf of the International AIDS Society.
       </copyrightinformation>
      </abstract>
      <authorlist completeyn="Y">
       <author validyn="Y">
        <lastname>
         Ford
        </lastname>
        <forename>
         Nathan
        </forename>
        <initials>
         N
        </initials>
        <identifier source="ORCID">
         0000-0003-1482-3967
        </identifier>
        <affiliationinfo>
         <affiliation>
          Department of HIV, Hepatitis and Sexually Transmitted Infections, World Health Organization, Geneva, Switzerland.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Vitoria
        </lastname>
        <forename>
         Marco
        </forename>
        <initials>
         M
        </initials>
        <affiliationinfo>
         <affiliation>
          Department of HIV, Hepatitis and Sexually Transmitted Infections, World Health Organization, Geneva, Switzerland.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Rangaraj
        </lastname>
        <forename>
         Ajay
        </forename>
        <initials>
         A
        </initials>
        <affiliationinfo>
         <affiliation>
          Department of HIV, Hepatitis and Sexually Transmitted Infections, World Health Organization, Geneva, Switzerland.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Norris
        </lastname>
        <forename>
         Susan L
        </forename>
        <initials>
         SL
        </initials>
        <identifier source="ORCID">
         0000-0002-0042-2452
        </identifier>
        <affiliationinfo>
         <affiliation>
          Science Division, Quality of Norms and Standards Department, World Health Organization, Geneva, Switzerland.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Calmy
        </lastname>
        <forename>
         Alexandra
        </forename>
        <initials>
         A
        </initials>
        <identifier source="ORCID">
         0000-0002-1137-6826
        </identifier>
        <affiliationinfo>
         <affiliation>
          HIV/AIDS Unit, Division of Infectious Diseases, Geneva University Hospitals, Geneva, Switzerland.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Doherty
        </lastname>
        <forename>
         Meg
        </forename>
        <initials>
         M
        </initials>
        <affiliationinfo>
         <affiliation>
          Department of HIV, Hepatitis and Sexually Transmitted Infections, World Health Organization, Geneva, Switzerland.
         </affiliation>
        </affiliationinfo>
       </author>
      </authorlist>
      <language>
       eng
      </language>
      <grantlist completeyn="Y">
       <grant>
        <agency>
         Bill and Melinda Gates Foundation
        </agency>
        <country>
         International
        </country>
       </grant>
      </grantlist>
      <publicationtypelist>
       <publicationtype ui="D016428">
        Journal Article
       </publicationtype>
       <publicationtype ui="D016454">
        Review
       </publicationtype>
       <publicationtype ui="D013485">
        Research Support, Non-U.S. Gov't
       </publicationtype>
      </publicationtypelist>
     </article>
     <medlinejournalinfo>
      <country>
       Switzerland
      </country>
      <medlineta>
       J Int AIDS Soc
      </medlineta>
      <nlmuniqueid>
       101478566
      </nlmuniqueid>
      <issnlinking>
       1758-2652
      </issnlinking>
     </medlinejournalinfo>
     <citationsubset>
      IM
     </citationsubset>
     <citationsubset>
      X
     </citationsubset>
     <keywordlist owner="NOTNLM">
      <keyword majortopicyn="Y">
       COVID-19
      </keyword>
      <keyword majortopicyn="Y">
       HIV
      </keyword>
      <keyword majortopicyn="Y">
       MERS
      </keyword>
      <keyword majortopicyn="Y">
       SARS
      </keyword>
      <keyword majortopicyn="Y">
       antiretroviral therapy
      </keyword>
      <keyword majortopicyn="Y">
       coronavirus
      </keyword>
     </keywordlist>
    </medlinecitation>
    <pubmeddata>
     <history>
      <pubmedpubdate pubstatus="received">
       <year>
        2020
       </year>
       <month>
        02
       </month>
       <day>
        23
       </day>
      </pubmedpubdate>
      <pubmedpubdate pubstatus="revised">
       <year>
        2020
       </year>
       <month>
        03
       </month>
       <day>
        17
       </day>
      </pubmedpubdate>
      <pubmedpubdate pubstatus="accepted">
       <year>
        2020
       </year>
       <month>
        03
       </month>
       <day>
        20
       </day>
      </pubmedpubdate>
      <pubmedpubdate pubstatus="entrez">
       <year>
        2020
       </year>
       <month>
        4
       </month>
       <day>
        16
       </day>
       <hour>
        6
       </hour>
       <minute>
        0
       </minute>
      </pubmedpubdate>
      <pubmedpubdate pubstatus="pubmed">
       <year>
        2020
       </year>
       <month>
        4
       </month>
       <day>
        16
       </day>
       <hour>
        6
       </hour>
       <minute>
        0
       </minute>
      </pubmedpubdate>
      <pubmedpubdate pubstatus="medline">
       <year>
        2020
       </year>
       <month>
        4
       </month>
       <day>
        16
       </day>
       <hour>
        6
       </hour>
       <minute>
        0
       </minute>
      </pubmedpubdate>
     </history>
     <publicationstatus>
      ppublish
     </publicationstatus>
     <articleidlist>
      <articleid idtype="pubmed">
       32293807
      </articleid>
      <articleid idtype="doi">
       10.1002/jia2.25489
      </articleid>
     </articleidlist>
     <referencelist>
      <title>
       REFERENCES
      </title>
      <reference>
       <citation>
        Zhou Y, Vedantham P, Lu K, Agudelo J, Carrion R Jr, Nunneley JW, et al. Protease inhibitors targeting coronavirus and filovirus entry. Antiviral Res. 2015;116:76-84.
       </citation>
      </reference>
      <reference>
       <citation>
        Chan KS, Lai ST, Chu CM, Tsui E, Tam CY, Wong MM, et al. Treatment of severe acute respiratory syndrome with lopinavir/ritonavir: a multicentre retrospective matched cohort study. Hong Kong Med J. 2003;9:399-406.
       </citation>
      </reference>
      <reference>
       <citation>
        Choi WS, Kang CI, Kim Y, Choi JP, Joh JS, Shin HS, et al. Clinical presentation and outcomes of middle east respiratory syndrome in the Republic of Korea. Infect Chemother. 2016;48:118-26.
       </citation>
      </reference>
      <reference>
       <citation>
        de Wilde AH, Jochmans D, Posthuma CC, Zevenhoven-Dobbe JC, van Nieuwkoop S, Bestebroer TM, et al. Screening of an FDA-approved compound library identifies four small-molecule inhibitors of Middle East respiratory syndrome coronavirus replication in cell culture. Antimicrob Agents Chemother. 2014;58:4875-84.
       </citation>
      </reference>
      <reference>
       <citation>
        Chan JF, Yao Y, Yeung ML, Deng W, Bao L, Jia L, et al. Treatment with lopinavir/ritonavir or interferon-beta1b improves outcome of MERS-CoV infection in a nonhuman primate model of common marmoset. J Infect Dis. 2015;212:1904-13.
       </citation>
      </reference>
      <reference>
       <citation>
        Jin YH, Cai L, Cheng ZS, Cheng H, Deng T, Fan YP, et al. A rapid advice guideline for the diagnosis and treatment of 2019 novel coronavirus (2019-nCoV) infected pneumonia (standard version). Mil Med Res. 2020;7:4.
       </citation>
      </reference>
      <reference>
       <citation>
        Tan EL, Ooi EE, Lin CY, Tan HC, Ling AE, Lim B, et al. Inhibition of SARS coronavirus infection in vitro with clinically approved antiviral drugs. Emerg Infect Dis. 2004;10:581-6.
       </citation>
      </reference>
      <reference>
       <citation>
        Morra ME, Van Thanh L, Kamel MG, Ghazy AA, Altibi AMA, Dat LM, et al. Clinical outcomes of current medical approaches for Middle East respiratory syndrome: a systematic review and meta-analysis. Rev Med Virol. 2018;28:e1977.
       </citation>
      </reference>
      <reference>
       <citation>
        Momattin H, Al-Ali AY, Al-Tawfiq JA. A Systematic Review of therapeutic agents for the treatment of the Middle East Respiratory Syndrome Coronavirus (MERS-CoV). Travel Med Infect Dis. 2019;30:9-18.
       </citation>
      </reference>
      <reference>
       <citation>
        Beck B, Shin B, Choi Y, Park S, Kang K. Predicting commercially available antiviral drugs that may act on the novel coronavirus (2019-nCoV), Wuhan, China through a drug-target interaction deep learning model. bioRxiv. 2020.
       </citation>
      </reference>
      <reference>
       <citation>
        Dayer M, Taleb-Gassabi S, Dayer M. Lopinavir; A potent drug against coronavirus infection: insight from molecular docking study. Archiv Clin Infect Dis. 2017;12:e13823.
       </citation>
      </reference>
      <reference>
       <citation>
        Guyatt GH, Oxman AD, Vist GE, Kunz R, Falck-Ytter Y, Alonso-Coello P, et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ. 2008;336(7650):924-6.
       </citation>
      </reference>
      <reference>
       <citation>
        Macconnachie AA, Collins TC, Seaton RA, Kennedy DH. Three men, a paint brush and a coronavirus. Int J STD AIDS. 2007;18:132-3.
       </citation>
      </reference>
      <reference>
       <citation>
        Wang XF, Yuan J, Zheng YJ, Chen J, Bao YM, Wang YR, et al. Retracted: clinical and epidemiological characteristics of 34 children with 2019 novel coronavirus infection in Shenzhen. Zhonghua Er Ke Za Zhi. 2020;58:E008.
       </citation>
      </reference>
      <reference>
       <citation>
        Peiris JS, Chu CM, Cheng VC, Chan KS, Hung IF, Poon LL, et al. Clinical progression and viral load in a community outbreak of coronavirus-associated SARS pneumonia: a prospective study. Lancet. 2003;361:1767-72.
       </citation>
      </reference>
      <reference>
       <citation>
        Shalhoub S, AlZahrani A, Simhairi R, Mushtaq A. Successful recovery of MERS CoV pneumonia in a patient with acquired immunodeficiency syndrome: a case report. J Clin Virol. 2015;62:69-71.
       </citation>
      </reference>
      <reference>
       <citation>
        Wong AT, Tsang OT, Wong MY, Lim WL, Zheng BJ, Lee SS, et al. Coronavirus infection in an AIDS patient. AIDS. 2004;18:829-30.
       </citation>
      </reference>
      <reference>
       <citation>
        Chu CM, Cheng VC, Hung IF, Wong MM, Chan KH, Chan KS, et al. Role of lopinavir/ritonavir in the treatment of SARS: initial virological and clinical findings. Thorax. 2004;59:252-6.
       </citation>
      </reference>
      <reference>
       <citation>
        Spanakis N, Tsiodras S, Haagmans BL, Raj VS, Pontikis K, Koutsoukou A, et al. Virological and serological analysis of a recent Middle East respiratory syndrome coronavirus infection case on a triple combination antiviral regimen. Int J Antimicrob Agents. 2014;44:528-32.
       </citation>
      </reference>
      <reference>
       <citation>
        Meyer B, Basra A, Aberle S, Aberle J, Robibaro B, Wenisch C, et al. MERS-COV disease associated ARDS - a case report. Crit Care Med. 2015;43(12):308.
       </citation>
      </reference>
      <reference>
       <citation>
        Alhumaid S, Tobaiqy M, Albagshi M, Alrubaya A, Algharib F, Aldera A, et al. MERS-CoV transmitted from animal-to-human vs MERSCoV transmitted from human-to-human: comparison of virulence and therapeutic outcomes in a Saudi hospital. Trop J Pharmaceut Res. 2018;17(6):1155-64.
       </citation>
      </reference>
      <reference>
       <citation>
        Kim UJ, Won EJ, Kee SJ, Jung SI, Jang HC. Combination therapy with lopinavir/ritonavir, ribavirin and interferon-alpha for Middle East respiratory syndrome. Antivir Ther. 2016;21:455-9.
       </citation>
      </reference>
      <reference>
       <citation>
        Cao B, Wang Y, Wen D, Liu W, Wang J, Fan G, et al. A randomized, controlled, open-label study to evaluate the efficacy and safety of oral lopinavir/ritonavir. NEJM. 2020. [Epub ahead of print].
       </citation>
      </reference>
      <reference>
       <citation>
        Li Y, Xie Z, Lin W, Cai W, Wen C, Guan Y, et al. An exploratory randomized, controlled study on the efficacy and safety of lopinavir/ritonavir or arbidol treating adult patients hospitalized with mild/moderate COVID-19 (ELACOI). medRxiv preprint. https://doi.org/10.1101/2020.03.19.20038984
       </citation>
      </reference>
      <reference>
       <citation>
        Lim J, Jeon S, Shin HY, Kim MJ, Seong YM, Lee WJ, et al. Case of the index patient who caused tertiary transmission of COVID-19 infection in Korea: the application of lopinavir/ritonavir for the treatment of COVID-19 infected pneumonia monitored by quantitative RT-PCR. J Korean Med Sci. 2020;35:e79.
       </citation>
      </reference>
      <reference>
       <citation>
        Han W, Quan B, Guo Y, Zhang J, Lu Y, Feng G, et al. The course of clinical diagnosis and treatment of a case infected with coronavirus disease 2019. J Med Virol. 2020;92(5):461-3.
       </citation>
      </reference>
      <reference>
       <citation>
        Kim JY, Choe PG, Oh Y, Oh KJ, Kim J, Park SJ, et al. The first case of 2019 novel coronavirus pneumonia imported into Korea from Wuhan, China: implication for infection prevention and control measures. J Korean Med Sci. 2020;35:e61.
       </citation>
      </reference>
      <reference>
       <citation>
        Wang Z, Chen X, Lu Y, Chen F, Zhang W. Clinical characteristics and therapeutic procedure for four cases with 2019 novel coronavirus pneumonia receiving combined Chinese and Western medicine treatment. BioSci Trends. 2020;14(1):64-8.
       </citation>
      </reference>
      <reference>
       <citation>
        Young BE, Ong SWX, Kalimuddin S, Low JG, Tan SY, Loh J, et al. Epidemiologic features and clinical course of patients infected with SARS-CoV-2 in Singapore. JAMA. 2020.
       </citation>
      </reference>
      <reference>
       <citation>
        Liu F, Xu A, Zhang Y, Xuan W, Yan T, Pan K, et al. Patients of COVID-19 may benefit from sustained lopinavir-combined regimen and the increase of eosinophil may predict the outcome of COVID-19 progression. Int J Infect Dis. 2020:1-28.
       </citation>
      </reference>
      <reference>
       <citation>
        Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet. 2020;395:507-13.
       </citation>
      </reference>
      <reference>
       <citation>
        Jun C, Yun L, Xiuhung X, Ping L, Feng L, Tao L, et al. Efficacy of lopinavir, ritonavir and abidol for the treatment of new coronavirus pneumonia. Chinese. J Infect Dis. 2020;38.
       </citation>
      </reference>
      <reference>
       <citation>
        Deng L, Li C, Zeng Q, Liu X, Li X, Zhang H, et al. Arbidol combined with LPV/r versus LPV/r alone against Corona Virus Disease 2019: a retrospective cohort study. J Infect. 2020. [Epub ahead of print].
       </citation>
      </reference>
      <reference>
       <citation>
        Liu K, Chen Y, Lin R, Han K. Clinical feature of COVID-19 in elderly patients: a comparison with young and middle-aged patients. J Infect. 2020:1-12.
       </citation>
      </reference>
      <reference>
       <citation>
        Wan S, Xiang Y, Fang W, Zheng Y, Li B, Hu Y, et al. Clinical features and treatment of COVID-19 patients in Northeast Chongqing. J Med Virol. 2020. [Epub ahead of print].
       </citation>
      </reference>
      <reference>
       <citation>
        Cai Q, Yang M, Liu D, Chen J, Shu D, Xia J, et al. Experimental treatment with favipiravir for COVID-19: an open-label control study. Engineering. 2020:1-13.
       </citation>
      </reference>
      <reference>
       <citation>
        WHO. Update of recommendations on first- and second-line antiretroviral regimens. Geneva: World Health Organization; 2019.
       </citation>
      </reference>
      <reference>
       <citation>
        Chen XP, Li GH, Tang XP, Xiong Y, Chen XJ, Cao Y. Lack of severe acute respiratory syndrome in 19 AIDS patients hospitalized together. J Acquir Immune Defic Syndr. 2003;34:242-3.
       </citation>
      </reference>
      <reference>
       <citation>
        Park SY, Lee JS, Son JS, Ko JH, Peck KR, Jung Y, et al. Post-exposure prophylaxis for Middle East respiratory syndrome in healthcare workers. J Hosp Infect. 2019;101:42-6.
       </citation>
      </reference>
      <reference>
       <citation>
        Guo W, Ming F, Dong Y, Zhang Q, Zhang X, Mo P, et al. A survey for COVID-19 among HIV/AIDS patients in two Districts of Wuhan, China. Lancet. 2020 [cited 2020 Apr 1]. Preprint. Available from: https://ssrn.com/abstract=3550029
       </citation>
      </reference>
      <reference>
       <citation>
        Muller MP, McGeer A, Straus SE, Hawryluck L, Gold WL. Clinical trials and novel pathogens: lessons learned from SARS. Emerg Infect Dis. 2004;10:389-94.
       </citation>
      </reference>
     </referencelist>
    </pubmeddata>
   </pubmedarticle>
   <pubmedarticle>
    <medlinecitation owner="NLM" status="Publisher">
     <pmid version="1">
      32292906
     </pmid>
     <daterevised>
      <year>
       2020
      </year>
      <month>
       04
      </month>
      <day>
       18
      </day>
     </daterevised>
     <article pubmodel="Print-Electronic">
      <journal>
       <issn issntype="Electronic">
        2590-0986
       </issn>
       <journalissue citedmedium="Internet">
        <pubdate>
         <year>
          2020
         </year>
         <month>
          Apr
         </month>
         <day>
          04
         </day>
        </pubdate>
       </journalissue>
       <title>
        Medicine in drug discovery
       </title>
       <isoabbreviation>
        Med Drug Discov
       </isoabbreviation>
      </journal>
      <articletitle>
       The role of afferent pulmonary innervation in poor prognosis of acute respiratory distress syndrome in COVID-19 patients and proposed use of resiniferatoxin (RTX) to improve patient outcomes in advanced disease state: A review.
      </articletitle>
      <pagination>
       <medlinepgn>
        100033
       </medlinepgn>
      </pagination>
      <elocationid eidtype="doi" validyn="Y">
       10.1016/j.medidd.2020.100033
      </elocationid>
      <abstract>
       <abstracttext>
        Acute respiratory distress is one of the major causes of mortality associated with COVID-19 disease. Many patients will require intensive care with ventilatory support. Despite progress and best efforts, the mortality rates projected remain high. Historical data outlook points towards 80% expected fatality for patients progressing to advanced pulmonary disease, even when hospitalized in the intensive care unit. This is particularly true among the patient population over 65. Novel life-saving strategies are desperately needed to mitigate the high mortality that will be associated with the late stage SARS-CoV-2 viral infection associated with the fatal respiratory distress. We hypothesize that the morbidity, severity of the disease, and underlying physiological events leading to mortality are closely linked to the TRPV1 expressing neuronal system (afferent/efferent neurons) in the lungs. TRPV1 expressing cells are responsible for pain transmission, inflammation and immunomodulation throughout the entire pulmonary system and are modulating the processes associated with localized cytokine release (storm) and overall rapid disease progression. We suggest that therapeutic approaches targeting TRPV1 containing nerve fibers in the lungs will modulate the inflammatory and immune signal activity, leading to reduced mortality and better overall outcomes. We also propose to further explore the use of resiniferatoxin (RTX), an ultra-potent TRPV1 agonist currently in clinical trials for cancer and osteoarthritis pain, as a possible ablating agent of TRPV1 positive pulmonary pathways in patients with advanced COVID-19 disease.
       </abstracttext>
       <copyrightinformation>
        © 2020 Published by Elsevier B.V.
       </copyrightinformation>
      </abstract>
      <authorlist completeyn="Y">
       <author validyn="Y">
        <lastname>
         Nahama
        </lastname>
        <forename>
         Alexis
        </forename>
        <initials>
         A
        </initials>
        <affiliationinfo>
         <affiliation>
          Sorrento, Therapeutics Inc. 4955 Directors' Place, San Diego, CA, 92121, United States of America.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Ramachandran
        </lastname>
        <forename>
         Roshni
        </forename>
        <initials>
         R
        </initials>
        <affiliationinfo>
         <affiliation>
          Sorrento, Therapeutics Inc. 4955 Directors' Place, San Diego, CA, 92121, United States of America.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Cisternas
        </lastname>
        <forename>
         Alvaro Francisco
        </forename>
        <initials>
         AF
        </initials>
        <affiliationinfo>
         <affiliation>
          Sorrento, Therapeutics Inc. 4955 Directors' Place, San Diego, CA, 92121, United States of America.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Ji
        </lastname>
        <forename>
         Henry
        </forename>
        <initials>
         H
        </initials>
        <affiliationinfo>
         <affiliation>
          Sorrento, Therapeutics Inc. 4955 Directors' Place, San Diego, CA, 92121, United States of America.
         </affiliation>
        </affiliationinfo>
       </author>
      </authorlist>
      <language>
       eng
      </language>
      <publicationtypelist>
       <publicationtype ui="D016428">
        Journal Article
       </publicationtype>
       <publicationtype ui="D016454">
        Review
       </publicationtype>
      </publicationtypelist>
      <articledate datetype="Electronic">
       <year>
        2020
       </year>
       <month>
        04
       </month>
       <day>
        04
       </day>
      </articledate>
     </article>
     <medlinejournalinfo>
      <country>
       Netherlands
      </country>
      <medlineta>
       Med Drug Discov
      </medlineta>
      <nlmuniqueid>
       101765689
      </nlmuniqueid>
      <issnlinking>
       2590-0986
      </issnlinking>
     </medlinejournalinfo>
     <keywordlist owner="NOTNLM">
      <keyword majortopicyn="N">
       ARDS
      </keyword>
      <keyword majortopicyn="N">
       Acute Respiratory Distress Syndrome
      </keyword>
      <keyword majortopicyn="N">
       COVID-19, SARS-CoV-2
      </keyword>
      <keyword majortopicyn="N">
       Coronavirus
      </keyword>
      <keyword majortopicyn="N">
       Cytokine Storm
      </keyword>
      <keyword majortopicyn="N">
       Inflammation
      </keyword>
      <keyword majortopicyn="N">
       Innervation
      </keyword>
      <keyword majortopicyn="N">
       Lungs
      </keyword>
      <keyword majortopicyn="N">
       RTX
      </keyword>
      <keyword majortopicyn="N">
       Resiniferatoxin
      </keyword>
      <keyword majortopicyn="N">
       TRPV1
      </keyword>
     </keywordlist>
    </medlinecitation>
    <pubmeddata>
     <history>
      <pubmedpubdate pubstatus="received">
       <year>
        2020
       </year>
       <month>
        03
       </month>
       <day>
        30
       </day>
      </pubmedpubdate>
      <pubmedpubdate pubstatus="accepted">
       <year>
        2020
       </year>
       <month>
        03
       </month>
       <day>
        31
       </day>
      </pubmedpubdate>
      <pubmedpubdate pubstatus="entrez">
       <year>
        2020
       </year>
       <month>
        4
       </month>
       <day>
        16
       </day>
       <hour>
        6
       </hour>
       <minute>
        0
       </minute>
      </pubmedpubdate>
      <pubmedpubdate pubstatus="pubmed">
       <year>
        2020
       </year>
       <month>
        4
       </month>
       <day>
        16
       </day>
       <hour>
        6
       </hour>
       <minute>
        0
       </minute>
      </pubmedpubdate>
      <pubmedpubdate pubstatus="medline">
       <year>
        2020
       </year>
       <month>
        4
       </month>
       <day>
        16
       </day>
       <hour>
        6
       </hour>
       <minute>
        0
       </minute>
      </pubmedpubdate>
     </history>
     <publicationstatus>
      aheadofprint
     </publicationstatus>
     <articleidlist>
      <articleid idtype="pubmed">
       32292906
      </articleid>
      <articleid idtype="doi">
       10.1016/j.medidd.2020.100033
      </articleid>
      <articleid idtype="pii">
       S2590-0986(20)30020-8
      </articleid>
      <articleid idtype="pii">
       100033
      </articleid>
      <articleid idtype="pmc">
       PMC7147194
      </articleid>
     </articleidlist>
     <?pmcsd ?>
     <referencelist>
      <reference>
       <citation>
        Basic Clin Pharmacol Toxicol. 2016 Nov;119(5):421-427
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         27090778
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
    </pubmeddata>
   </pubmedarticle>
   <pubmedarticle>
    <medlinecitation owner="NLM" status="PubMed-not-MEDLINE">
     <pmid version="1">
      32292826
     </pmid>
     <daterevised>
      <year>
       2020
      </year>
      <month>
       04
      </month>
      <day>
       17
      </day>
     </daterevised>
     <article pubmodel="Electronic-eCollection">
      <journal>
       <issn issntype="Print">
        2398-502X
       </issn>
       <journalissue citedmedium="Print">
        <volume>
         5
        </volume>
        <pubdate>
         <year>
          2020
         </year>
        </pubdate>
       </journalissue>
       <title>
        Wellcome open research
       </title>
       <isoabbreviation>
        Wellcome Open Res
       </isoabbreviation>
      </journal>
      <articletitle>
       A living systematic review protocol for COVID-19 clinical trial registrations.
      </articletitle>
      <pagination>
       <medlinepgn>
        60
       </medlinepgn>
      </pagination>
      <elocationid eidtype="doi" validyn="Y">
       10.12688/wellcomeopenres.15821.1
      </elocationid>
      <abstract>
       <abstracttext>
        Since the coronavirus disease 2019 (COVID-19) outbreak was identified in December 2019 in Wuhan, China, a strong response from the research community has been observed with the proliferation of independent clinical trials assessing diagnostic methods, therapeutic and prophylactic strategies. While there is no intervention for the prevention or treatment of COVID-19 with proven clinical efficacy to date, tools to distil the current research landscape by intervention, level of evidence and those studies likely powered to address future research questions is essential. This living systematic review aims to provide an open, accessible and frequently updated resource summarising the characteristics of COVID-19 clinical trial registrations. Weekly search updates of the WHO International Clinical Trials Registry Platform (ICTRP) and source registries will be conducted. Data extraction by two independent reviewers of trial characteristic variables including categorisation of trial design, geographic location, intervention type and targets, level of evidence and intervention adaptability to low resource settings will be completed. Descriptive and thematic synthesis will be conducted. A searchable and interactive visualisation of the results database will be created, and made openly available online. Weekly results from the continued search updates will be published and made available on the Infectious Diseases Data Observatory (IDDO) website ( COVID-19 website). This living systematic review will provide a useful resource of COVID-19 clinical trial registrations for researchers in a rapidly evolving context. In the future, this sustained review will allow prioritisation of research targets for individual patient data meta-analysis.
       </abstracttext>
       <copyrightinformation>
        Copyright: © 2020 Maguire BJ and Guérin PJ.
       </copyrightinformation>
      </abstract>
      <authorlist completeyn="Y">
       <author validyn="Y">
        <lastname>
         Maguire
        </lastname>
        <forename>
         Brittany J
        </forename>
        <initials>
         BJ
        </initials>
        <identifier source="ORCID">
         https://orcid.org/0000-0002-6333-0109
        </identifier>
        <affiliationinfo>
         <affiliation>
          Infectious Diseases Data Observatory (IDDO), Oxford, UK.
         </affiliation>
        </affiliationinfo>
        <affiliationinfo>
         <affiliation>
          Centre for Tropical Medicine and Global Health, Nuffield Department of Medicine, University of Oxford, Oxford, UK.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Guérin
        </lastname>
        <forename>
         Philippe J
        </forename>
        <initials>
         PJ
        </initials>
        <affiliationinfo>
         <affiliation>
          Infectious Diseases Data Observatory (IDDO), Oxford, UK.
         </affiliation>
        </affiliationinfo>
        <affiliationinfo>
         <affiliation>
          Centre for Tropical Medicine and Global Health, Nuffield Department of Medicine, University of Oxford, Oxford, UK.
         </affiliation>
        </affiliationinfo>
       </author>
      </authorlist>
      <language>
       eng
      </language>
      <publicationtypelist>
       <publicationtype ui="D016428">
        Journal Article
       </publicationtype>
      </publicationtypelist>
      <articledate datetype="Electronic">
       <year>
        2020
       </year>
       <month>
        04
       </month>
       <day>
        02
       </day>
      </articledate>
     </article>
     <medlinejournalinfo>
      <country>
       England
      </country>
      <medlineta>
       Wellcome Open Res
      </medlineta>
      <nlmuniqueid>
       101696457
      </nlmuniqueid>
      <issnlinking>
       2398-502X
      </issnlinking>
     </medlinejournalinfo>
     <keywordlist owner="NOTNLM">
      <keyword majortopicyn="N">
       COVID-19
      </keyword>
      <keyword majortopicyn="N">
       Living systematic review
      </keyword>
      <keyword majortopicyn="N">
       clinical trials
      </keyword>
      <keyword majortopicyn="N">
       coronavirus
      </keyword>
      <keyword majortopicyn="N">
       emerging infections
      </keyword>
     </keywordlist>
     <coistatement>
      No competing interests were disclosed.
     </coistatement>
    </medlinecitation>
    <pubmeddata>
     <history>
      <pubmedpubdate pubstatus="accepted">
       <year>
        2020
       </year>
       <month>
        03
       </month>
       <day>
        31
       </day>
      </pubmedpubdate>
      <pubmedpubdate pubstatus="entrez">
       <year>
        2020
       </year>
       <month>
        4
       </month>
       <day>
        16
       </day>
       <hour>
        6
       </hour>
       <minute>
        0
       </minute>
      </pubmedpubdate>
      <pubmedpubdate pubstatus="pubmed">
       <year>
        2020
       </year>
       <month>
        4
       </month>
       <day>
        16
       </day>
       <hour>
        6
       </hour>
       <minute>
        0
       </minute>
      </pubmedpubdate>
      <pubmedpubdate pubstatus="medline">
       <year>
        2020
       </year>
       <month>
        4
       </month>
       <day>
        16
       </day>
       <hour>
        6
       </hour>
       <minute>
        1
       </minute>
      </pubmedpubdate>
     </history>
     <publicationstatus>
      epublish
     </publicationstatus>
     <articleidlist>
      <articleid idtype="pubmed">
       32292826
      </articleid>
      <articleid idtype="doi">
       10.12688/wellcomeopenres.15821.1
      </articleid>
      <articleid idtype="pmc">
       PMC7141164
      </articleid>
     </articleidlist>
     <referencelist>
      <reference>
       <citation>
        J Biomed Inform. 2009 Apr;42(2):377-81
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         18929686
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Lancet Infect Dis. 2014 Dec;14(12):1259-70
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         25213733
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Sci Data. 2016 Mar 15;3:160018
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         26978244
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        PLoS Med. 2014 Feb 18;11(2):e1001603
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         24558353
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        J Clin Epidemiol. 2017 Nov;91:23-30
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         28912002
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        J Biomed Inform. 2019 Jul;95:103208
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         31078660
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
    </pubmeddata>
   </pubmedarticle>
   <pubmedarticle>
    <medlinecitation owner="NLM" status="Publisher">
     <pmid version="1">
      32292689
     </pmid>
     <daterevised>
      <year>
       2020
      </year>
      <month>
       04
      </month>
      <day>
       18
      </day>
     </daterevised>
     <article pubmodel="Print-Electronic">
      <journal>
       <issn issntype="Print">
        2211-3835
       </issn>
       <journalissue citedmedium="Print">
        <pubdate>
         <year>
          2020
         </year>
         <month>
          Feb
         </month>
         <day>
          27
         </day>
        </pubdate>
       </journalissue>
       <title>
        Acta pharmaceutica Sinica. B
       </title>
       <isoabbreviation>
        Acta Pharm Sin B
       </isoabbreviation>
      </journal>
      <articletitle>
       Analysis of therapeutic targets for SARS-CoV-2 and discovery of potential drugs by computational methods.
      </articletitle>
      <elocationid eidtype="doi" validyn="Y">
       10.1016/j.apsb.2020.02.008
      </elocationid>
      <abstract>
       <abstracttext>
        SARS-CoV-2 has caused tens of thousands of infections and more than one thousand deaths. There are currently no registered therapies for treating coronavirus infections. Because of time consuming process of new drug development, drug repositioning may be the only solution to the epidemic of sudden infectious diseases. We systematically analyzed all the proteins encoded by SARS-CoV-2 genes, compared them with proteins from other coronaviruses, predicted their structures, and built 19 structures that could be done by homology modeling. By performing target-based virtual ligand screening, a total of 21 targets (including two human targets) were screened against compound libraries including ZINC drug database and our own database of natural products. Structure and screening results of important targets such as 3-chymotrypsin-like protease (3CLpro), Spike, RNA-dependent RNA polymerase (RdRp), and papain like protease (PLpro) were discussed in detail. In addition, a database of 78 commonly used anti-viral drugs including those currently on the market and undergoing clinical trials for SARS-CoV-2 was constructed. Possible targets of these compounds and potential drugs acting on a certain target were predicted. This study will provide new lead compounds and targets for further
        <i>
         in vitro
        </i>
        and
        <i>
         in vivo
        </i>
        studies of SARS-CoV-2, new insights for those drugs currently ongoing clinical studies, and also possible new strategies for drug repositioning to treat SARS-CoV-2 infections.
       </abstracttext>
       <copyrightinformation>
        © 2020 Chinese Pharmaceutical Association and Institute of Materia Medica, Chinese Academy of Medical Sciences. Production and hosting by Elsevier B.V.
       </copyrightinformation>
      </abstract>
      <authorlist completeyn="Y">
       <author validyn="Y">
        <lastname>
         Wu
        </lastname>
        <forename>
         Canrong
        </forename>
        <initials>
         C
        </initials>
        <affiliationinfo>
         <affiliation>
          Hubei Key Laboratory of Natural Medicinal Chemistry and Resource Evaluation, School of Pharmacy, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Liu
        </lastname>
        <forename>
         Yang
        </forename>
        <initials>
         Y
        </initials>
        <affiliationinfo>
         <affiliation>
          Wuya College of Innovation, Key Laboratory of Structure-Based Drug Design &amp; Discovery, Ministry of Education, Shenyang Pharmaceutical University, Shenyang 110016, China.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Yang
        </lastname>
        <forename>
         Yueying
        </forename>
        <initials>
         Y
        </initials>
        <affiliationinfo>
         <affiliation>
          Wuya College of Innovation, Key Laboratory of Structure-Based Drug Design &amp; Discovery, Ministry of Education, Shenyang Pharmaceutical University, Shenyang 110016, China.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Zhang
        </lastname>
        <forename>
         Peng
        </forename>
        <initials>
         P
        </initials>
        <affiliationinfo>
         <affiliation>
          Wuya College of Innovation, Key Laboratory of Structure-Based Drug Design &amp; Discovery, Ministry of Education, Shenyang Pharmaceutical University, Shenyang 110016, China.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Zhong
        </lastname>
        <forename>
         Wu
        </forename>
        <initials>
         W
        </initials>
        <affiliationinfo>
         <affiliation>
          National Engineering Research Center for the Emergency Drug, Beijing Institute of Pharmacology and Toxicology, Beijing 100850, China.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Wang
        </lastname>
        <forename>
         Yali
        </forename>
        <initials>
         Y
        </initials>
        <affiliationinfo>
         <affiliation>
          Wuya College of Innovation, Key Laboratory of Structure-Based Drug Design &amp; Discovery, Ministry of Education, Shenyang Pharmaceutical University, Shenyang 110016, China.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Wang
        </lastname>
        <forename>
         Qiqi
        </forename>
        <initials>
         Q
        </initials>
        <affiliationinfo>
         <affiliation>
          Wuya College of Innovation, Key Laboratory of Structure-Based Drug Design &amp; Discovery, Ministry of Education, Shenyang Pharmaceutical University, Shenyang 110016, China.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Xu
        </lastname>
        <forename>
         Yang
        </forename>
        <initials>
         Y
        </initials>
        <affiliationinfo>
         <affiliation>
          Wuya College of Innovation, Key Laboratory of Structure-Based Drug Design &amp; Discovery, Ministry of Education, Shenyang Pharmaceutical University, Shenyang 110016, China.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Li
        </lastname>
        <forename>
         Mingxue
        </forename>
        <initials>
         M
        </initials>
        <affiliationinfo>
         <affiliation>
          Wuya College of Innovation, Key Laboratory of Structure-Based Drug Design &amp; Discovery, Ministry of Education, Shenyang Pharmaceutical University, Shenyang 110016, China.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Li
        </lastname>
        <forename>
         Xingzhou
        </forename>
        <initials>
         X
        </initials>
        <affiliationinfo>
         <affiliation>
          National Engineering Research Center for the Emergency Drug, Beijing Institute of Pharmacology and Toxicology, Beijing 100850, China.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Zheng
        </lastname>
        <forename>
         Mengzhu
        </forename>
        <initials>
         M
        </initials>
        <affiliationinfo>
         <affiliation>
          Hubei Key Laboratory of Natural Medicinal Chemistry and Resource Evaluation, School of Pharmacy, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Chen
        </lastname>
        <forename>
         Lixia
        </forename>
        <initials>
         L
        </initials>
        <affiliationinfo>
         <affiliation>
          Wuya College of Innovation, Key Laboratory of Structure-Based Drug Design &amp; Discovery, Ministry of Education, Shenyang Pharmaceutical University, Shenyang 110016, China.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Li
        </lastname>
        <forename>
         Hua
        </forename>
        <initials>
         H
        </initials>
        <affiliationinfo>
         <affiliation>
          Hubei Key Laboratory of Natural Medicinal Chemistry and Resource Evaluation, School of Pharmacy, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China.
         </affiliation>
        </affiliationinfo>
        <affiliationinfo>
         <affiliation>
          Wuya College of Innovation, Key Laboratory of Structure-Based Drug Design &amp; Discovery, Ministry of Education, Shenyang Pharmaceutical University, Shenyang 110016, China.
         </affiliation>
        </affiliationinfo>
       </author>
      </authorlist>
      <language>
       eng
      </language>
      <publicationtypelist>
       <publicationtype ui="D016428">
        Journal Article
       </publicationtype>
      </publicationtypelist>
      <articledate datetype="Electronic">
       <year>
        2020
       </year>
       <month>
        02
       </month>
       <day>
        27
       </day>
      </articledate>
     </article>
     <medlinejournalinfo>
      <country>
       Netherlands
      </country>
      <medlineta>
       Acta Pharm Sin B
      </medlineta>
      <nlmuniqueid>
       101600560
      </nlmuniqueid>
      <issnlinking>
       2211-3835
      </issnlinking>
     </medlinejournalinfo>
     <keywordlist owner="NOTNLM">
      <keyword majortopicyn="N">
       3CLpro, 3-chymotrypsin-like protease
      </keyword>
      <keyword majortopicyn="N">
       Drug repurposing
      </keyword>
      <keyword majortopicyn="N">
       E, envelope
      </keyword>
      <keyword majortopicyn="N">
       Homology modeling
      </keyword>
      <keyword majortopicyn="N">
       M, membrane protein
      </keyword>
      <keyword majortopicyn="N">
       Molecular docking
      </keyword>
      <keyword majortopicyn="N">
       N, nucleocapsid protein
      </keyword>
      <keyword majortopicyn="N">
       Nsp, non-structure protein
      </keyword>
      <keyword majortopicyn="N">
       ORF, open reading frame
      </keyword>
      <keyword majortopicyn="N">
       PDB, protein data bank
      </keyword>
      <keyword majortopicyn="N">
       RdRp, RNA-dependence RNA polymerase
      </keyword>
      <keyword majortopicyn="N">
       Remdesivir
      </keyword>
      <keyword majortopicyn="N">
       S, Spike
      </keyword>
      <keyword majortopicyn="N">
       SARS-CoV-2
      </keyword>
      <keyword majortopicyn="N">
       SUD, SARS unique domain
      </keyword>
      <keyword majortopicyn="N">
       UB, ubiquitin-like domain
      </keyword>
     </keywordlist>
     <coistatement>
      The authors claim that the researchers in this study have no conflict of interest.
     </coistatement>
    </medlinecitation>
    <pubmeddata>
     <history>
      <pubmedpubdate pubstatus="received">
       <year>
        2020
       </year>
       <month>
        02
       </month>
       <day>
        12
       </day>
      </pubmedpubdate>
      <pubmedpubdate pubstatus="revised">
       <year>
        2020
       </year>
       <month>
        02
       </month>
       <day>
        17
       </day>
      </pubmedpubdate>
      <pubmedpubdate pubstatus="accepted">
       <year>
        2020
       </year>
       <month>
        02
       </month>
       <day>
        18
       </day>
      </pubmedpubdate>
      <pubmedpubdate pubstatus="entrez">
       <year>
        2020
       </year>
       <month>
        4
       </month>
       <day>
        16
       </day>
       <hour>
        6
       </hour>
       <minute>
        0
       </minute>
      </pubmedpubdate>
      <pubmedpubdate pubstatus="pubmed">
       <year>
        2020
       </year>
       <month>
        4
       </month>
       <day>
        16
       </day>
       <hour>
        6
       </hour>
       <minute>
        0
       </minute>
      </pubmedpubdate>
      <pubmedpubdate pubstatus="medline">
       <year>
        2020
       </year>
       <month>
        4
       </month>
       <day>
        16
       </day>
       <hour>
        6
       </hour>
       <minute>
        0
       </minute>
      </pubmedpubdate>
     </history>
     <publicationstatus>
      aheadofprint
     </publicationstatus>
     <articleidlist>
      <articleid idtype="pubmed">
       32292689
      </articleid>
      <articleid idtype="doi">
       10.1016/j.apsb.2020.02.008
      </articleid>
      <articleid idtype="pii">
       S2211-3835(20)30299-9
      </articleid>
      <articleid idtype="pmc">
       PMC7102550
      </articleid>
     </articleidlist>
     <?pmcsd ?>
     <referencelist>
      <reference>
       <citation>
        Virology. 2006 Jun 20;350(1):15-25
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         16510163
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        J Comput Aided Mol Des. 2012 Jun;26(6):675-86
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         22569591
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Nature. 2013 Nov 28;503(7477):535-8
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         24172901
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Virus Res. 2015 Apr 16;202:120-34
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         25445340
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        J Virol. 2016 Jan 20;90(7):3627-39
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         26792741
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Biochem Biophys Res Commun. 2008 Feb 15;366(3):738-44
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         18082623
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        PLoS Biol. 2005 Oct;3(10):e324
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         16128623
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Exp Mol Pathol. 2020 Apr;113:104350
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         31805278
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Viruses. 2012 Apr;4(4):557-80
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         22590686
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        J Med Chem. 2016 Jul 28;59(14):6595-628
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         26878082
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        J Virol. 2003 Aug;77(16):8801-11
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         12885899
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Antimicrob Agents Chemother. 2014 Aug;58(8):4885-93
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         24841273
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Lancet Infect Dis. 2013 Oct;13(10):859-66
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         23933067
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        J Virol. 2015 Dec;89(23):11820-33
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         26378163
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Chembiochem. 2008 Dec 15;9(18):3037-45
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         19031435
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        J Virol. 2013 Jul;87(14):7790-2
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         23678167
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Clin Microbiol Rev. 2007 Oct;20(4):660-94
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         17934078
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        J Virol. 2015 Apr;89(7):3659-70
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         25589660
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Virus Res. 2014 Dec 19;194:200-10
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         25451066
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Antivir Chem Chemother. 2006;17(5):285-9
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         17176633
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        J Chem Inf Model. 2012 Jul 23;52(7):1757-68
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         22587354
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        J Virol. 2004 Dec;78(24):13600-12
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         15564471
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        J Virol. 2004 Jul;78(14):7833-8
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         15220459
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        N Engl J Med. 2003 May 15;348(20):1986-94
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         12682352
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Nat Rev Drug Discov. 2016 May;15(5):327-47
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         26868298
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        N Engl J Med. 2012 Nov 8;367(19):1814-20
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         23075143
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        J Virol. 2008 May;82(9):4471-9
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         18305050
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Nature. 2003 Nov 27;426(6965):450-4
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         14647384
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        J Virol. 2011 May;85(9):4122-34
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         21325420
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        EMBO J. 2006 Oct 18;25(20):4933-42
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         17024178
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Proc Natl Acad Sci U S A. 2006 Aug 22;103(34):12885-90
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         16912115
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Protein Cell. 2014 May;5(5):369-81
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         24622840
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        J Biol Chem. 2015 Jan 30;290(5):3172-82
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         25505178
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Proc Natl Acad Sci U S A. 2003 Nov 11;100(23):13190-5
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         14585926
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Antiviral Res. 2014 Jan;101:122-30
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         24269475
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Proc Natl Acad Sci U S A. 2014 Apr 1;111(13):4970-5
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         24599590
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        J Infect. 2013 Dec;67(6):606-16
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         24096239
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        J Med Chem. 1999 Mar 11;42(5):791-804
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         10072678
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Proc Natl Acad Sci U S A. 2005 Sep 27;102(39):14040-5
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         16169905
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Science. 2005 Sep 16;309(5742):1864-8
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         16166518
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Lancet Infect Dis. 2014 Nov;14(11):1090-1095
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         25278221
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Nucleic Acids Res. 2005 Jul 1;33(Web Server issue):W284-8
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         15980471
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
    </pubmeddata>
   </pubmedarticle>
   <pubmedarticle>
    <medlinecitation owner="NLM" status="Publisher">
     <pmid version="1">
      32292626
     </pmid>
     <daterevised>
      <year>
       2020
      </year>
      <month>
       04
      </month>
      <day>
       18
      </day>
     </daterevised>
     <article pubmodel="Print-Electronic">
      <journal>
       <issn issntype="Print">
        2095-8099
       </issn>
       <journalissue citedmedium="Print">
        <pubdate>
         <year>
          2020
         </year>
         <month>
          Mar
         </month>
         <day>
          18
         </day>
        </pubdate>
       </journalissue>
       <title>
        Engineering (Beijing, China)
       </title>
       <isoabbreviation>
        Engineering (Beijing)
       </isoabbreviation>
      </journal>
      <articletitle>
       Core Outcome Set for Clinical Trials on Coronavirus Disease 2019 (COS-COVID).
      </articletitle>
      <elocationid eidtype="doi" validyn="Y">
       10.1016/j.eng.2020.03.002
      </elocationid>
      <abstract>
       <abstracttext>
        Since its outbreak in December 2019, a series of clinical trials on Coronavirus Disease 2019 (COVID-19) have been registered or carried out. However, the significant heterogeneity and less critical outcomes of such trials may be leading to a waste of research resources. This study aimed to develop a core outcome set (COS) for clinical trials on COVID-19 in order to tackle the outcome issues. The study was conducted according to the Core Outcome Measures in Effectiveness Trials (COMET) handbook (version 1.0), a guideline for COS development. A research group was set up that included experts in respiratory and critical medicine, traditional Chinese medicine, evidence-based medicine, clinical pharmacology, and statistics, in addition to medical journal editors. Clinical trial registry websites (chictr.org.cn and clinicaltrials.gov) were searched to retrieve clinical trial protocols and outcomes in order to form an outcome pool. A total of 78 clinical trial protocols on COVID-19 were included and 259 outcomes were collected. After standardization, 132 outcomes were identified within seven different categories, of which 58 were selected to develop a preliminary outcome list for further consensus. After two rounds of Delphi survey and one consensus meeting, the most important outcomes for the different clinical classifications of COVID-19 were identified and determined to constitute the COS for clinical trials on COVID-19 (COS-COVID). The COS-COVID includes one outcome for the mild type (time to 2019-nCoV reverse transcription-polymerase chain reaction (RT-PCR) negativity), four outcomes for the ordinary type (length of hospital stay, composite events, score of clinical symptoms, and time to 2019-nCoV RT-PCR negativity), five outcomes for the severe type (composite events, length of hospital stay, arterial oxygen partial pressure (PaO
        <sub>
         2
        </sub>
        )/fraction of inspired oxygen (FiO
        <sub>
         2
        </sub>
        ), duration of mechanical ventilation, and time to 2019-nCoV RT-PCR negativity), one outcome for critical type (all-cause mortality), and one outcome for rehabilitation period (pulmonary function). The COS-COVID is currently the most valuable and practical clinical outcome set for the evaluation of intervention effect, and is useful for evidence assessment and decision-making. With a deepening understanding of COVID-19 and application feedback, the COS-COVID should be continuously updated.
       </abstracttext>
       <copyrightinformation>
        © 2020 THE AUTHORS. Published by Elsevier LTD on behalf of Chinese Academy of Engineering and Higher Education Press Limited Company.
       </copyrightinformation>
      </abstract>
      <authorlist completeyn="Y">
       <author validyn="Y">
        <lastname>
         Jin
        </lastname>
        <forename>
         Xinyao
        </forename>
        <initials>
         X
        </initials>
        <affiliationinfo>
         <affiliation>
          Evidence-Based Medicine Center, Tianjin University of Traditional Chinese Medicine, Tianjin 301617, China.
         </affiliation>
        </affiliationinfo>
        <affiliationinfo>
         <affiliation>
          Chinese Clinical Trials Core Outcome Set Research Center, Tianjin 301617, China.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Pang
        </lastname>
        <forename>
         Bo
        </forename>
        <initials>
         B
        </initials>
        <affiliationinfo>
         <affiliation>
          Evidence-Based Medicine Center, Tianjin University of Traditional Chinese Medicine, Tianjin 301617, China.
         </affiliation>
        </affiliationinfo>
        <affiliationinfo>
         <affiliation>
          Chinese Clinical Trials Core Outcome Set Research Center, Tianjin 301617, China.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Zhang
        </lastname>
        <forename>
         Junhua
        </forename>
        <initials>
         J
        </initials>
        <affiliationinfo>
         <affiliation>
          Evidence-Based Medicine Center, Tianjin University of Traditional Chinese Medicine, Tianjin 301617, China.
         </affiliation>
        </affiliationinfo>
        <affiliationinfo>
         <affiliation>
          Chinese Clinical Trials Core Outcome Set Research Center, Tianjin 301617, China.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Liu
        </lastname>
        <forename>
         Qingquan
        </forename>
        <initials>
         Q
        </initials>
        <affiliationinfo>
         <affiliation>
          Beijing Hospital of Traditional Chinese Medicine, Capital Medical University, Beijing 100010, China.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Yang
        </lastname>
        <forename>
         Zhongqi
        </forename>
        <initials>
         Z
        </initials>
        <affiliationinfo>
         <affiliation>
          The First Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou 510405, China.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Feng
        </lastname>
        <forename>
         Jihong
        </forename>
        <initials>
         J
        </initials>
        <affiliationinfo>
         <affiliation>
          The Second Affiliated Hospital of Tianjin University of Traditional Chinese Medicine, Tianjin 300150, China.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Liu
        </lastname>
        <forename>
         Xuezheng
        </forename>
        <initials>
         X
        </initials>
        <affiliationinfo>
         <affiliation>
          The First Teaching Hospital of Tianjin University of Traditional Chinese Medicine, Tianjin 300201, China.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Zhang
        </lastname>
        <forename>
         Lei
        </forename>
        <initials>
         L
        </initials>
        <affiliationinfo>
         <affiliation>
          The First Teaching Hospital of Tianjin University of Traditional Chinese Medicine, Tianjin 300201, China.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Wang
        </lastname>
        <forename>
         Baohe
        </forename>
        <initials>
         B
        </initials>
        <affiliationinfo>
         <affiliation>
          The Second Affiliated Hospital of Tianjin University of Traditional Chinese Medicine, Tianjin 300150, China.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Huang
        </lastname>
        <forename>
         Yuhong
        </forename>
        <initials>
         Y
        </initials>
        <affiliationinfo>
         <affiliation>
          The Second Affiliated Hospital of Tianjin University of Traditional Chinese Medicine, Tianjin 300150, China.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Josephine Fauci
        </lastname>
        <forename>
         Alice
        </forename>
        <initials>
         A
        </initials>
        <affiliationinfo>
         <affiliation>
          Istituto Superiore di Sanità, Rome 00161, Italy.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Ma
        </lastname>
        <forename>
         Yuling
        </forename>
        <initials>
         Y
        </initials>
        <affiliationinfo>
         <affiliation>
          University of Oxford, Oxford OX1 3PT, UK.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Soo Lee
        </lastname>
        <forename>
         Myeong
        </forename>
        <initials>
         M
        </initials>
        <affiliationinfo>
         <affiliation>
          Korea Institute of Oriental Medicine, Daejeon 34054, Republic of Korea.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Yuan
        </lastname>
        <forename>
         Wei'an
        </forename>
        <initials>
         W
        </initials>
        <affiliationinfo>
         <affiliation>
          Shuguang Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai 200120, China.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Xie
        </lastname>
        <forename>
         Yanming
        </forename>
        <initials>
         Y
        </initials>
        <affiliationinfo>
         <affiliation>
          Institute of Basic Research in Clinical Medicine, China Academy of Chinese Medical Sciences, Beijing 100700, China.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Tang
        </lastname>
        <forename>
         Jianyuan
        </forename>
        <initials>
         J
        </initials>
        <affiliationinfo>
         <affiliation>
          Affiliated Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu, 610075, China.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Gao
        </lastname>
        <forename>
         Rui
        </forename>
        <initials>
         R
        </initials>
        <affiliationinfo>
         <affiliation>
          Xiyuan Hospital, China Academy of Chinese Medical Sciences, Beijing 100091, China.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Du
        </lastname>
        <forename>
         Liang
        </forename>
        <initials>
         L
        </initials>
        <affiliationinfo>
         <affiliation>
          Chinese Clinical Trials Core Outcome Set Research Center, Tianjin 301617, China.
         </affiliation>
        </affiliationinfo>
        <affiliationinfo>
         <affiliation>
          The Chinese Cochrane Center, West China Hospital of Sichuan University, Chengdu 610041, China.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Zhang
        </lastname>
        <forename>
         Shuo
        </forename>
        <initials>
         S
        </initials>
        <affiliationinfo>
         <affiliation>
          The Second Affiliated Hospital of Tianjin University of Traditional Chinese Medicine, Tianjin 300150, China.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Qi
        </lastname>
        <forename>
         Hanmei
        </forename>
        <initials>
         H
        </initials>
        <affiliationinfo>
         <affiliation>
          The First Affiliated Hospital of Nanjing Medical University, Nanjing 210029, China.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Sun
        </lastname>
        <forename>
         Yu
        </forename>
        <initials>
         Y
        </initials>
        <affiliationinfo>
         <affiliation>
          Suqian People's Hospital of Nanjing Drum-Tower Hospital Group, Suqian 223800, China.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Zheng
        </lastname>
        <forename>
         Wenke
        </forename>
        <initials>
         W
        </initials>
        <affiliationinfo>
         <affiliation>
          Evidence-Based Medicine Center, Tianjin University of Traditional Chinese Medicine, Tianjin 301617, China.
         </affiliation>
        </affiliationinfo>
        <affiliationinfo>
         <affiliation>
          Chinese Clinical Trials Core Outcome Set Research Center, Tianjin 301617, China.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Yang
        </lastname>
        <forename>
         Fengwen
        </forename>
        <initials>
         F
        </initials>
        <affiliationinfo>
         <affiliation>
          Evidence-Based Medicine Center, Tianjin University of Traditional Chinese Medicine, Tianjin 301617, China.
         </affiliation>
        </affiliationinfo>
        <affiliationinfo>
         <affiliation>
          Chinese Clinical Trials Core Outcome Set Research Center, Tianjin 301617, China.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Chua
        </lastname>
        <forename>
         Huizi
        </forename>
        <initials>
         H
        </initials>
        <affiliationinfo>
         <affiliation>
          Evidence-Based Medicine Center, Tianjin University of Traditional Chinese Medicine, Tianjin 301617, China.
         </affiliation>
        </affiliationinfo>
        <affiliationinfo>
         <affiliation>
          Chinese Clinical Trials Core Outcome Set Research Center, Tianjin 301617, China.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Wang
        </lastname>
        <forename>
         Keyi
        </forename>
        <initials>
         K
        </initials>
        <affiliationinfo>
         <affiliation>
          Evidence-Based Medicine Center, Tianjin University of Traditional Chinese Medicine, Tianjin 301617, China.
         </affiliation>
        </affiliationinfo>
        <affiliationinfo>
         <affiliation>
          Chinese Clinical Trials Core Outcome Set Research Center, Tianjin 301617, China.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Ou
        </lastname>
        <forename>
         Yi
        </forename>
        <initials>
         Y
        </initials>
        <affiliationinfo>
         <affiliation>
          Evidence-Based Medicine Center, Tianjin University of Traditional Chinese Medicine, Tianjin 301617, China.
         </affiliation>
        </affiliationinfo>
        <affiliationinfo>
         <affiliation>
          Chinese Clinical Trials Core Outcome Set Research Center, Tianjin 301617, China.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Huang
        </lastname>
        <forename>
         Ming
        </forename>
        <initials>
         M
        </initials>
        <affiliationinfo>
         <affiliation>
          Evidence-Based Medicine Center, Tianjin University of Traditional Chinese Medicine, Tianjin 301617, China.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Zhu
        </lastname>
        <forename>
         Yan
        </forename>
        <initials>
         Y
        </initials>
        <affiliationinfo>
         <affiliation>
          Tianjin State Key Laboratory of Modern Chinese Medicine, Tianjin University of Traditional Chinese Medicine, Tianjin 301617, China.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Yu
        </lastname>
        <forename>
         Jiajie
        </forename>
        <initials>
         J
        </initials>
        <affiliationinfo>
         <affiliation>
          Chinese Clinical Trials Core Outcome Set Research Center, Tianjin 301617, China.
         </affiliation>
        </affiliationinfo>
        <affiliationinfo>
         <affiliation>
          The Chinese Cochrane Center, West China Hospital of Sichuan University, Chengdu 610041, China.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Tian
        </lastname>
        <forename>
         Jinhui
        </forename>
        <initials>
         J
        </initials>
        <affiliationinfo>
         <affiliation>
          Lanzhou University, Lanzhou 730000, China.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Zhao
        </lastname>
        <forename>
         Min
        </forename>
        <initials>
         M
        </initials>
        <affiliationinfo>
         <affiliation>
          The First Affiliated Hospital of Henan University of Chinese Medicine, Zhengzhou 450099, China.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Hu
        </lastname>
        <forename>
         Jingqing
        </forename>
        <initials>
         J
        </initials>
        <affiliationinfo>
         <affiliation>
          Institute of Basic Theory for Chinese Medicine, China Academy of Chinese Medicine Science, Beijing 100700, China.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Yao
        </lastname>
        <forename>
         Chen
        </forename>
        <initials>
         C
        </initials>
        <affiliationinfo>
         <affiliation>
          Peking University First Hospital, Beijing 100034, China.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Li
        </lastname>
        <forename>
         Youping
        </forename>
        <initials>
         Y
        </initials>
        <affiliationinfo>
         <affiliation>
          Chinese Clinical Trials Core Outcome Set Research Center, Tianjin 301617, China.
         </affiliation>
        </affiliationinfo>
        <affiliationinfo>
         <affiliation>
          The Chinese Cochrane Center, West China Hospital of Sichuan University, Chengdu 610041, China.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Zhang
        </lastname>
        <forename>
         Boli
        </forename>
        <initials>
         B
        </initials>
        <affiliationinfo>
         <affiliation>
          Evidence-Based Medicine Center, Tianjin University of Traditional Chinese Medicine, Tianjin 301617, China.
         </affiliation>
        </affiliationinfo>
        <affiliationinfo>
         <affiliation>
          Tianjin State Key Laboratory of Modern Chinese Medicine, Tianjin University of Traditional Chinese Medicine, Tianjin 301617, China.
         </affiliation>
        </affiliationinfo>
       </author>
      </authorlist>
      <language>
       eng
      </language>
      <publicationtypelist>
       <publicationtype ui="D016428">
        Journal Article
       </publicationtype>
      </publicationtypelist>
      <articledate datetype="Electronic">
       <year>
        2020
       </year>
       <month>
        03
       </month>
       <day>
        18
       </day>
      </articledate>
     </article>
     <medlinejournalinfo>
      <country>
       China
      </country>
      <medlineta>
       Engineering (Beijing)
      </medlineta>
      <nlmuniqueid>
       101673395
      </nlmuniqueid>
      <issnlinking>
       2095-8099
      </issnlinking>
     </medlinejournalinfo>
     <keywordlist owner="NOTNLM">
      <keyword majortopicyn="N">
       2019-nCoV
      </keyword>
      <keyword majortopicyn="N">
       COVID-19
      </keyword>
      <keyword majortopicyn="N">
       Clinical trials
      </keyword>
      <keyword majortopicyn="N">
       Core outcome set
      </keyword>
      <keyword majortopicyn="N">
       Coronavirus disease
      </keyword>
     </keywordlist>
     <coistatement>
      The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
     </coistatement>
    </medlinecitation>
    <pubmeddata>
     <history>
      <pubmedpubdate pubstatus="entrez">
       <year>
        2020
       </year>
       <month>
        4
       </month>
       <day>
        16
       </day>
       <hour>
        6
       </hour>
       <minute>
        0
       </minute>
      </pubmedpubdate>
      <pubmedpubdate pubstatus="pubmed">
       <year>
        2020
       </year>
       <month>
        4
       </month>
       <day>
        16
       </day>
       <hour>
        6
       </hour>
       <minute>
        0
       </minute>
      </pubmedpubdate>
      <pubmedpubdate pubstatus="medline">
       <year>
        2020
       </year>
       <month>
        4
       </month>
       <day>
        16
       </day>
       <hour>
        6
       </hour>
       <minute>
        0
       </minute>
      </pubmedpubdate>
     </history>
     <publicationstatus>
      aheadofprint
     </publicationstatus>
     <articleidlist>
      <articleid idtype="pubmed">
       32292626
      </articleid>
      <articleid idtype="doi">
       10.1016/j.eng.2020.03.002
      </articleid>
      <articleid idtype="pii">
       S2095-8099(20)30042-4
      </articleid>
      <articleid idtype="pmc">
       PMC7102592
      </articleid>
     </articleidlist>
     <?pmcsd ?>
     <referencelist>
      <reference>
       <citation>
        Trials. 2012 Jul 02;13:103
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         22747787
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Trials. 2012 Aug 06;13:132
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         22867278
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Trials. 2017 Jun 20;18(Suppl 3):280
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         28681707
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Trials. 2019 Feb 11;20(1):116
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         30744706
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
    </pubmeddata>
   </pubmedarticle>
   <pubmedarticle>
    <medlinecitation owner="NLM" status="PubMed-not-MEDLINE">
     <pmid version="1">
      32291351
     </pmid>
     <daterevised>
      <year>
       2020
      </year>
      <month>
       04
      </month>
      <day>
       15
      </day>
     </daterevised>
     <article pubmodel="Electronic">
      <journal>
       <issn issntype="Print">
        2379-5077
       </issn>
       <journalissue citedmedium="Print">
        <volume>
         5
        </volume>
        <issue>
         2
        </issue>
        <pubdate>
         <year>
          2020
         </year>
         <month>
          Apr
         </month>
         <day>
          14
         </day>
        </pubdate>
       </journalissue>
       <title>
        mSystems
       </title>
       <isoabbreviation>
        mSystems
       </isoabbreviation>
      </journal>
      <articletitle>
       Repurposing Didanosine as a Potential Treatment for COVID-19 Using Single-Cell RNA Sequencing Data.
      </articletitle>
      <elocationid eidtype="pii" validyn="Y">
       e00297-20
      </elocationid>
      <elocationid eidtype="doi" validyn="Y">
       10.1128/mSystems.00297-20
      </elocationid>
      <abstract>
       <abstracttext>
        As of today (7 April 2020), more than 81,000 people around the world have died from the coronavirus disease 19 (COVID-19) pandemic. There is no approved drug or vaccine for COVID-19, although more than 10 clinical trials have been launched to test potential drugs. In an urgent response to this pandemic, I developed a bioinformatics pipeline to identify compounds and drug candidates to potentially treat COVID-19. This pipeline is based on publicly available single-cell RNA sequencing (scRNA-seq) data and the drug perturbation database "Library of Integrated Network-Based Cellular Signatures" (LINCS). I developed a ranking score system that prioritizes these drugs or small molecules. The four drugs with the highest total score are didanosine, benzyl-quinazolin-4-yl-amine, camptothecin, and RO-90-7501. In conclusion, I have demonstrated the utility of bioinformatics for identifying drugs than can be repurposed for potentially treating COVID-19 patients.
       </abstracttext>
       <copyrightinformation>
        Copyright © 2020 Alakwaa.
       </copyrightinformation>
      </abstract>
      <authorlist completeyn="Y">
       <author validyn="Y">
        <lastname>
         Alakwaa
        </lastname>
        <forename>
         Fadhl M
        </forename>
        <initials>
         FM
        </initials>
        <identifier source="ORCID">
         https://orcid.org/0000-0001-5349-7960
        </identifier>
        <affiliationinfo>
         <affiliation>
          Department of Neurology, University of Michigan, Ann Arbor, Michigan, USA alakwaaf@med.umich.edu.
         </affiliation>
        </affiliationinfo>
       </author>
      </authorlist>
      <language>
       eng
      </language>
      <publicationtypelist>
       <publicationtype ui="D016428">
        Journal Article
       </publicationtype>
      </publicationtypelist>
      <articledate datetype="Electronic">
       <year>
        2020
       </year>
       <month>
        04
       </month>
       <day>
        14
       </day>
      </articledate>
     </article>
     <medlinejournalinfo>
      <country>
       United States
      </country>
      <medlineta>
       mSystems
      </medlineta>
      <nlmuniqueid>
       101680636
      </nlmuniqueid>
      <issnlinking>
       2379-5077
      </issnlinking>
     </medlinejournalinfo>
     <keywordlist owner="NOTNLM">
      <keyword majortopicyn="N">
       COVID-19
      </keyword>
      <keyword majortopicyn="N">
       drug
      </keyword>
      <keyword majortopicyn="N">
       repurposing
      </keyword>
     </keywordlist>
    </medlinecitation>
    <pubmeddata>
     <history>
      <pubmedpubdate pubstatus="entrez">
       <year>
        2020
       </year>
       <month>
        4
       </month>
       <day>
        16
       </day>
       <hour>
        6
       </hour>
       <minute>
        0
       </minute>
      </pubmedpubdate>
      <pubmedpubdate pubstatus="pubmed">
       <year>
        2020
       </year>
       <month>
        4
       </month>
       <day>
        16
       </day>
       <hour>
        6
       </hour>
       <minute>
        0
       </minute>
      </pubmedpubdate>
      <pubmedpubdate pubstatus="medline">
       <year>
        2020
       </year>
       <month>
        4
       </month>
       <day>
        16
       </day>
       <hour>
        6
       </hour>
       <minute>
        1
       </minute>
      </pubmedpubdate>
     </history>
     <publicationstatus>
      epublish
     </publicationstatus>
     <articleidlist>
      <articleid idtype="pubmed">
       32291351
      </articleid>
      <articleid idtype="pii">
       5/2/e00297-20
      </articleid>
      <articleid idtype="doi">
       10.1128/mSystems.00297-20
      </articleid>
     </articleidlist>
    </pubmeddata>
   </pubmedarticle>
   <pubmedarticle>
    <medlinecitation owner="NLM" status="Publisher">
     <pmid version="1">
      32291112
     </pmid>
     <daterevised>
      <year>
       2020
      </year>
      <month>
       04
      </month>
      <day>
       17
      </day>
     </daterevised>
     <article pubmodel="Print-Electronic">
      <journal>
       <issn issntype="Electronic">
        1873-3735
       </issn>
       <journalissue citedmedium="Internet">
        <pubdate>
         <year>
          2020
         </year>
         <month>
          Apr
         </month>
         <day>
          09
         </day>
        </pubdate>
       </journalissue>
       <title>
        Trends in pharmacological sciences
       </title>
       <isoabbreviation>
        Trends Pharmacol. Sci.
       </isoabbreviation>
      </journal>
      <articletitle>
       Ongoing Clinical Trials for the Management of the COVID-19 Pandemic.
      </articletitle>
      <elocationid eidtype="pii" validyn="Y">
       S0165-6147(20)30070-5
      </elocationid>
      <elocationid eidtype="doi" validyn="Y">
       10.1016/j.tips.2020.03.006
      </elocationid>
      <abstract>
       <abstracttext>
        COVID-19 has rapidly developed into a worldwide pandemic with a significant health and economic burden. There are currently no approved treatments or preventative therapeutic strategies. Hundreds of clinical studies have been registered with the intention of discovering effective treatments. Here, we review currently registered interventional clinical trials for the treatment and prevention of COVID-19 to provide an overall summary and insight into the global response.
       </abstracttext>
       <copyrightinformation>
        Copyright © 2020 Elsevier Ltd. All rights reserved.
       </copyrightinformation>
      </abstract>
      <authorlist completeyn="Y">
       <author validyn="Y">
        <lastname>
         Lythgoe
        </lastname>
        <forename>
         Mark P
        </forename>
        <initials>
         MP
        </initials>
        <affiliationinfo>
         <affiliation>
          Department of Surgery and Cancer, Imperial College London, Hammersmith Hospital, Du Cane Road, London, W12 0HS, UK. Electronic address: M.Lythgoe@imperial.ac.uk.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Middleton
        </lastname>
        <forename>
         Paul
        </forename>
        <initials>
         P
        </initials>
        <affiliationinfo>
         <affiliation>
          Department of Metabolism, Digestion and Reproduction, Imperial College London, St Marys Hospital, Praed Street, London, W21, NY, UK.
         </affiliation>
        </affiliationinfo>
       </author>
      </authorlist>
      <language>
       eng
      </language>
      <publicationtypelist>
       <publicationtype ui="D016428">
        Journal Article
       </publicationtype>
      </publicationtypelist>
      <articledate datetype="Electronic">
       <year>
        2020
       </year>
       <month>
        04
       </month>
       <day>
        09
       </day>
      </articledate>
     </article>
     <medlinejournalinfo>
      <country>
       England
      </country>
      <medlineta>
       Trends Pharmacol Sci
      </medlineta>
      <nlmuniqueid>
       7906158
      </nlmuniqueid>
      <issnlinking>
       0165-6147
      </issnlinking>
     </medlinejournalinfo>
     <citationsubset>
      IM
     </citationsubset>
     <keywordlist owner="NOTNLM">
      <keyword majortopicyn="N">
       2019-nCoV
      </keyword>
      <keyword majortopicyn="N">
       COVID-19
      </keyword>
      <keyword majortopicyn="N">
       SARS-CoV-2
      </keyword>
      <keyword majortopicyn="N">
       coronavirus
      </keyword>
      <keyword majortopicyn="N">
       pandemic
      </keyword>
     </keywordlist>
    </medlinecitation>
    <pubmeddata>
     <history>
      <pubmedpubdate pubstatus="received">
       <year>
        2020
       </year>
       <month>
        03
       </month>
       <day>
        29
       </day>
      </pubmedpubdate>
      <pubmedpubdate pubstatus="accepted">
       <year>
        2020
       </year>
       <month>
        03
       </month>
       <day>
        29
       </day>
      </pubmedpubdate>
      <pubmedpubdate pubstatus="entrez">
       <year>
        2020
       </year>
       <month>
        4
       </month>
       <day>
        16
       </day>
       <hour>
        6
       </hour>
       <minute>
        0
       </minute>
      </pubmedpubdate>
      <pubmedpubdate pubstatus="pubmed">
       <year>
        2020
       </year>
       <month>
        4
       </month>
       <day>
        16
       </day>
       <hour>
        6
       </hour>
       <minute>
        0
       </minute>
      </pubmedpubdate>
      <pubmedpubdate pubstatus="medline">
       <year>
        2020
       </year>
       <month>
        4
       </month>
       <day>
        16
       </day>
       <hour>
        6
       </hour>
       <minute>
        0
       </minute>
      </pubmedpubdate>
     </history>
     <publicationstatus>
      aheadofprint
     </publicationstatus>
     <articleidlist>
      <articleid idtype="pubmed">
       32291112
      </articleid>
      <articleid idtype="pii">
       S0165-6147(20)30070-5
      </articleid>
      <articleid idtype="doi">
       10.1016/j.tips.2020.03.006
      </articleid>
      <articleid idtype="pmc">
       PMC7144665
      </articleid>
     </articleidlist>
     <referencelist>
      <reference>
       <citation>
        Cell Res. 2020 Mar;30(3):269-271
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         32020029
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Biosci Trends. 2020 Mar 16;14(1):72-73
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         32074550
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Pharmacol Ther. 2016 Aug;164:195-203
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         27133570
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Thorax. 2004 Mar;59(3):252-6
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         14985565
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        N Engl J Med. 2020 Mar 5;382(10):929-936
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         32004427
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Nat Rev Microbiol. 2016 Aug;14(8):523-34
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         27344959
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Antimicrob Agents Chemother. 1998 Dec;42(12):3218-24
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         9835517
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Health Policy. 2008 Oct;88(1):110-20
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         18436332
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        J Virol. 2010 Jan;84(1):44-51
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         19864389
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Lancet. 2020 Feb 22;395(10224):565-574
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         32007145
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Lancet Respir Med. 2015 Jan;3(1):24-32
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         25529339
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Aging Dis. 2020 Mar 9;11(2):216-228
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         32257537
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Nat Rev Drug Discov. 2020 Mar;19(3):149-150
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         32127666
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        N Engl J Med. 2016 Jan 7;374(1):33-42
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         26735992
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Lancet. 2004 Sep 11-17;364(9438):911-2
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         15364170
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Nature. 2016 Mar 17;531(7594):381-5
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         26934220
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Nature. 2020 Mar;579(7799):321
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         32179860
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
    </pubmeddata>
   </pubmedarticle>
   <pubmedarticle>
    <medlinecitation owner="NLM" status="MEDLINE">
     <pmid version="1">
      32290293
     </pmid>
     <datecompleted>
      <year>
       2020
      </year>
      <month>
       04
      </month>
      <day>
       16
      </day>
     </datecompleted>
     <daterevised>
      <year>
       2020
      </year>
      <month>
       04
      </month>
      <day>
       16
      </day>
     </daterevised>
     <article pubmodel="Electronic">
      <journal>
       <issn issntype="Electronic">
        1422-0067
       </issn>
       <journalissue citedmedium="Internet">
        <volume>
         21
        </volume>
        <issue>
         7
        </issue>
        <pubdate>
         <year>
          2020
         </year>
         <month>
          Apr
         </month>
         <day>
          10
         </day>
        </pubdate>
       </journalissue>
       <title>
        International journal of molecular sciences
       </title>
       <isoabbreviation>
        Int J Mol Sci
       </isoabbreviation>
      </journal>
      <articletitle>
       A Review of SARS-CoV-2 and the Ongoing Clinical Trials.
      </articletitle>
      <elocationid eidtype="pii" validyn="Y">
       E2657
      </elocationid>
      <elocationid eidtype="doi" validyn="Y">
       10.3390/ijms21072657
      </elocationid>
      <abstract>
       <abstracttext>
        The sudden outbreak of 2019 novel coronavirus (2019-nCoV, later named SARS-CoV-2) in Wuhan, China, which rapidly grew into a global pandemic, marked the third introduction of a virulent coronavirus into the human society, affecting not only the healthcare system, but also the global economy. Although our understanding of coronaviruses has undergone a huge leap after two precedents, the effective approaches to treatment and epidemiological control are still lacking. In this article, we present a succinct overview of the epidemiology, clinical features, and molecular characteristics of SARS-CoV-2. We summarize the current epidemiological and clinical data from the initial Wuhan studies, and emphasize several features of SARS-CoV-2, which differentiate it from SARS-CoV and Middle East respiratory syndrome coronavirus (MERS-CoV), such as high variability of disease presentation. We systematize the current clinical trials that have been rapidly initiated after the outbreak of COVID-19 pandemic. Whereas the trials on SARS-CoV-2 genome-based specific vaccines and therapeutic antibodies are currently being tested, this solution is more long-term, as they require thorough testing of their safety. On the other hand, the repurposing of the existing therapeutic agents previously designed for other virus infections and pathologies happens to be the only practical approach as a rapid response measure to the emergent pandemic, as most of these agents have already been tested for their safety. These agents can be divided into two broad categories, those that can directly target the virus replication cycle, and those based on immunotherapy approaches either aimed to boost innate antiviral immune responses or alleviate damage induced by dysregulated inflammatory responses. The initial clinical studies revealed the promising therapeutic potential of several of such drugs, including
        <i>
         favipiravir
        </i>
        , a broad-spectrum antiviral drug that interferes with the viral replication, and
        <i>
         hydroxychloroquine
        </i>
        , the repurposed antimalarial drug that interferes with the virus endosomal entry pathway. We speculate that the current pandemic emergency will be a trigger for more systematic drug repurposing design approaches based on big data analysis.
       </abstracttext>
      </abstract>
      <authorlist completeyn="Y">
       <author validyn="Y">
        <lastname>
         Tu
        </lastname>
        <forename>
         Yung-Fang
        </forename>
        <initials>
         YF
        </initials>
        <affiliationinfo>
         <affiliation>
          Department of Medical Research, Taipei Veterans General Hospital, Taipei 11217, Taiwan.
         </affiliation>
        </affiliationinfo>
        <affiliationinfo>
         <affiliation>
          School of Medicine, National Yang-Ming University, Taipei 11221, Taiwan.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Chien
        </lastname>
        <forename>
         Chian-Shiu
        </forename>
        <initials>
         CS
        </initials>
        <affiliationinfo>
         <affiliation>
          Department of Medical Research, Taipei Veterans General Hospital, Taipei 11217, Taiwan.
         </affiliation>
        </affiliationinfo>
        <affiliationinfo>
         <affiliation>
          Institute of Pharmacology, National Yang-Ming University, Taipei 11221, Taiwan.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Yarmishyn
        </lastname>
        <forename>
         Aliaksandr A
        </forename>
        <initials>
         AA
        </initials>
        <affiliationinfo>
         <affiliation>
          Department of Medical Research, Taipei Veterans General Hospital, Taipei 11217, Taiwan.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Lin
        </lastname>
        <forename>
         Yi-Ying
        </forename>
        <initials>
         YY
        </initials>
        <affiliationinfo>
         <affiliation>
          Department of Medical Research, Taipei Veterans General Hospital, Taipei 11217, Taiwan.
         </affiliation>
        </affiliationinfo>
        <affiliationinfo>
         <affiliation>
          Institute of Pharmacology, National Yang-Ming University, Taipei 11221, Taiwan.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Luo
        </lastname>
        <forename>
         Yung-Hung
        </forename>
        <initials>
         YH
        </initials>
        <affiliationinfo>
         <affiliation>
          School of Medicine, National Yang-Ming University, Taipei 11221, Taiwan.
         </affiliation>
        </affiliationinfo>
        <affiliationinfo>
         <affiliation>
          Department of Chest Medicine, Taipei Veterans General Hospital, Taipei 11217, Taiwan.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Lin
        </lastname>
        <forename>
         Yi-Tsung
        </forename>
        <initials>
         YT
        </initials>
        <affiliationinfo>
         <affiliation>
          School of Medicine, National Yang-Ming University, Taipei 11221, Taiwan.
         </affiliation>
        </affiliationinfo>
        <affiliationinfo>
         <affiliation>
          Division of Infectious Diseases, Department of Medicine, Taipei Veterans General Hospital, Taipei 11217, Taiwan.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Lai
        </lastname>
        <forename>
         Wei-Yi
        </forename>
        <initials>
         WY
        </initials>
        <affiliationinfo>
         <affiliation>
          Department of Medical Research, Taipei Veterans General Hospital, Taipei 11217, Taiwan.
         </affiliation>
        </affiliationinfo>
        <affiliationinfo>
         <affiliation>
          Institute of Pharmacology, National Yang-Ming University, Taipei 11221, Taiwan.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Yang
        </lastname>
        <forename>
         De-Ming
        </forename>
        <initials>
         DM
        </initials>
        <affiliationinfo>
         <affiliation>
          Department of Medical Research, Taipei Veterans General Hospital, Taipei 11217, Taiwan.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Chou
        </lastname>
        <forename>
         Shih-Jie
        </forename>
        <initials>
         SJ
        </initials>
        <affiliationinfo>
         <affiliation>
          Department of Medical Research, Taipei Veterans General Hospital, Taipei 11217, Taiwan.
         </affiliation>
        </affiliationinfo>
        <affiliationinfo>
         <affiliation>
          Institute of Pharmacology, National Yang-Ming University, Taipei 11221, Taiwan.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Yang
        </lastname>
        <forename>
         Yi-Ping
        </forename>
        <initials>
         YP
        </initials>
        <affiliationinfo>
         <affiliation>
          Department of Medical Research, Taipei Veterans General Hospital, Taipei 11217, Taiwan.
         </affiliation>
        </affiliationinfo>
        <affiliationinfo>
         <affiliation>
          Institute of Pharmacology, National Yang-Ming University, Taipei 11221, Taiwan.
         </affiliation>
        </affiliationinfo>
        <affiliationinfo>
         <affiliation>
          Institute of Food Safety and Health Risk Assessment, School of Pharmaceutical Sciences, National Yang Ming University, Taipei 11221, Taiwan.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Wang
        </lastname>
        <forename>
         Mong-Lien
        </forename>
        <initials>
         ML
        </initials>
        <affiliationinfo>
         <affiliation>
          Department of Medical Research, Taipei Veterans General Hospital, Taipei 11217, Taiwan.
         </affiliation>
        </affiliationinfo>
        <affiliationinfo>
         <affiliation>
          School of Medicine, National Yang-Ming University, Taipei 11221, Taiwan.
         </affiliation>
        </affiliationinfo>
        <affiliationinfo>
         <affiliation>
          Institute of Food Safety and Health Risk Assessment, School of Pharmaceutical Sciences, National Yang Ming University, Taipei 11221, Taiwan.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Chiou
        </lastname>
        <forename>
         Shih-Hwa
        </forename>
        <initials>
         SH
        </initials>
        <affiliationinfo>
         <affiliation>
          Department of Medical Research, Taipei Veterans General Hospital, Taipei 11217, Taiwan.
         </affiliation>
        </affiliationinfo>
        <affiliationinfo>
         <affiliation>
          School of Medicine, National Yang-Ming University, Taipei 11221, Taiwan.
         </affiliation>
        </affiliationinfo>
        <affiliationinfo>
         <affiliation>
          Institute of Pharmacology, National Yang-Ming University, Taipei 11221, Taiwan.
         </affiliation>
        </affiliationinfo>
        <affiliationinfo>
         <affiliation>
          Genomic Research Center, Academia Sinica, Taipei 11529, Taiwan.
         </affiliation>
        </affiliationinfo>
       </author>
      </authorlist>
      <language>
       eng
      </language>
      <publicationtypelist>
       <publicationtype ui="D016428">
        Journal Article
       </publicationtype>
       <publicationtype ui="D016454">
        Review
       </publicationtype>
      </publicationtypelist>
      <articledate datetype="Electronic">
       <year>
        2020
       </year>
       <month>
        04
       </month>
       <day>
        10
       </day>
      </articledate>
     </article>
     <medlinejournalinfo>
      <country>
       Switzerland
      </country>
      <medlineta>
       Int J Mol Sci
      </medlineta>
      <nlmuniqueid>
       101092791
      </nlmuniqueid>
      <issnlinking>
       1422-0067
      </issnlinking>
     </medlinejournalinfo>
     <chemicallist>
      <chemical>
       <registrynumber>
        0
       </registrynumber>
       <nameofsubstance ui="D000998">
        Antiviral Agents
       </nameofsubstance>
      </chemical>
      <chemical>
       <registrynumber>
        0
       </registrynumber>
       <nameofsubstance ui="C000669933">
        COVID-19 vaccine
       </nameofsubstance>
      </chemical>
      <chemical>
       <registrynumber>
        0
       </registrynumber>
       <nameofsubstance ui="D007155">
        Immunologic Factors
       </nameofsubstance>
      </chemical>
      <chemical>
       <registrynumber>
        0
       </registrynumber>
       <nameofsubstance ui="D014765">
        Viral Vaccines
       </nameofsubstance>
      </chemical>
     </chemicallist>
     <supplmeshlist>
      <supplmeshname type="Disease" ui="C000657245">
       COVID-19
      </supplmeshname>
      <supplmeshname type="Protocol" ui="C000705127">
       COVID-19 drug treatment
      </supplmeshname>
      <supplmeshname type="Protocol" ui="C000705128">
       COVID-19 serotherapy
      </supplmeshname>
      <supplmeshname type="Organism" ui="C000656484">
       severe acute respiratory syndrome coronavirus 2
      </supplmeshname>
     </supplmeshlist>
     <citationsubset>
      IM
     </citationsubset>
     <meshheadinglist>
      <meshheading>
       <descriptorname majortopicyn="N" ui="D000998">
        Antiviral Agents
       </descriptorname>
       <qualifiername majortopicyn="Y" ui="Q000627">
        therapeutic use
       </qualifiername>
      </meshheading>
      <meshheading>
       <descriptorname majortopicyn="Y" ui="D000073640">
        Betacoronavirus
       </descriptorname>
       <qualifiername majortopicyn="N" ui="Q000737">
        chemistry
       </qualifiername>
       <qualifiername majortopicyn="N" ui="Q000235">
        genetics
       </qualifiername>
       <qualifiername majortopicyn="N" ui="Q000276">
        immunology
       </qualifiername>
       <qualifiername majortopicyn="N" ui="Q000502">
        physiology
       </qualifiername>
      </meshheading>
      <meshheading>
       <descriptorname majortopicyn="N" ui="D002986">
        Clinical Trials as Topic
       </descriptorname>
      </meshheading>
      <meshheading>
       <descriptorname majortopicyn="Y" ui="D018352">
        Coronavirus Infections
       </descriptorname>
       <qualifiername majortopicyn="N" ui="Q000175">
        diagnosis
       </qualifiername>
       <qualifiername majortopicyn="N" ui="Q000188">
        drug therapy
       </qualifiername>
       <qualifiername majortopicyn="N" ui="Q000453">
        epidemiology
       </qualifiername>
       <qualifiername majortopicyn="N" ui="Q000517">
        prevention &amp; control
       </qualifiername>
       <qualifiername majortopicyn="N" ui="Q000628">
        therapy
       </qualifiername>
       <qualifiername majortopicyn="N" ui="Q000821">
        virology
       </qualifiername>
      </meshheading>
      <meshheading>
       <descriptorname majortopicyn="N" ui="D016679">
        Genome, Viral
       </descriptorname>
      </meshheading>
      <meshheading>
       <descriptorname majortopicyn="N" ui="D006801">
        Humans
       </descriptorname>
      </meshheading>
      <meshheading>
       <descriptorname majortopicyn="N" ui="D007116">
        Immunization, Passive
       </descriptorname>
      </meshheading>
      <meshheading>
       <descriptorname majortopicyn="N" ui="D007155">
        Immunologic Factors
       </descriptorname>
       <qualifiername majortopicyn="Y" ui="Q000627">
        therapeutic use
       </qualifiername>
      </meshheading>
      <meshheading>
       <descriptorname majortopicyn="Y" ui="D058873">
        Pandemics
       </descriptorname>
      </meshheading>
      <meshheading>
       <descriptorname majortopicyn="Y" ui="D011024">
        Pneumonia, Viral
       </descriptorname>
       <qualifiername majortopicyn="N" ui="Q000175">
        diagnosis
       </qualifiername>
       <qualifiername majortopicyn="N" ui="Q000453">
        epidemiology
       </qualifiername>
       <qualifiername majortopicyn="N" ui="Q000628">
        therapy
       </qualifiername>
       <qualifiername majortopicyn="N" ui="Q000821">
        virology
       </qualifiername>
      </meshheading>
      <meshheading>
       <descriptorname majortopicyn="Y" ui="D014765">
        Viral Vaccines
       </descriptorname>
      </meshheading>
     </meshheadinglist>
     <keywordlist owner="NOTNLM">
      <keyword majortopicyn="N">
       ACE2
      </keyword>
      <keyword majortopicyn="N">
       COVID-19
      </keyword>
      <keyword majortopicyn="N">
       SARS-CoV-2
      </keyword>
      <keyword majortopicyn="N">
       clinical trials
      </keyword>
      <keyword majortopicyn="N">
       immunotherapy
      </keyword>
      <keyword majortopicyn="N">
       pneumonia
      </keyword>
      <keyword majortopicyn="N">
       replicase
      </keyword>
      <keyword majortopicyn="N">
       vaccine
      </keyword>
     </keywordlist>
    </medlinecitation>
    <pubmeddata>
     <history>
      <pubmedpubdate pubstatus="received">
       <year>
        2020
       </year>
       <month>
        03
       </month>
       <day>
        12
       </day>
      </pubmedpubdate>
      <pubmedpubdate pubstatus="revised">
       <year>
        2020
       </year>
       <month>
        04
       </month>
       <day>
        07
       </day>
      </pubmedpubdate>
      <pubmedpubdate pubstatus="accepted">
       <year>
        2020
       </year>
       <month>
        04
       </month>
       <day>
        08
       </day>
      </pubmedpubdate>
      <pubmedpubdate pubstatus="entrez">
       <year>
        2020
       </year>
       <month>
        4
       </month>
       <day>
        16
       </day>
       <hour>
        6
       </hour>
       <minute>
        0
       </minute>
      </pubmedpubdate>
      <pubmedpubdate pubstatus="pubmed">
       <year>
        2020
       </year>
       <month>
        4
       </month>
       <day>
        16
       </day>
       <hour>
        6
       </hour>
       <minute>
        0
       </minute>
      </pubmedpubdate>
      <pubmedpubdate pubstatus="medline">
       <year>
        2020
       </year>
       <month>
        4
       </month>
       <day>
        17
       </day>
       <hour>
        6
       </hour>
       <minute>
        0
       </minute>
      </pubmedpubdate>
     </history>
     <publicationstatus>
      epublish
     </publicationstatus>
     <articleidlist>
      <articleid idtype="pubmed">
       32290293
      </articleid>
      <articleid idtype="pii">
       ijms21072657
      </articleid>
      <articleid idtype="doi">
       10.3390/ijms21072657
      </articleid>
     </articleidlist>
    </pubmeddata>
   </pubmedarticle>
   <pubmedarticle>
    <medlinecitation owner="NLM" status="Publisher">
     <pmid version="1">
      32282502
     </pmid>
     <daterevised>
      <year>
       2020
      </year>
      <month>
       04
      </month>
      <day>
       13
      </day>
     </daterevised>
     <article pubmodel="Print-Electronic">
      <journal>
       <issn issntype="Electronic">
        1533-4023
       </issn>
       <journalissue citedmedium="Internet">
        <pubdate>
         <year>
          2020
         </year>
         <month>
          Apr
         </month>
         <day>
          02
         </day>
        </pubdate>
       </journalissue>
       <title>
        Journal of cardiovascular pharmacology
       </title>
       <isoabbreviation>
        J. Cardiovasc. Pharmacol.
       </isoabbreviation>
      </journal>
      <articletitle>
       Cardiovascular Considerations in Treating Patients with Coronavirus (COVID-19).
      </articletitle>
      <elocationid eidtype="doi" validyn="Y">
       10.1097/FJC.0000000000000836
      </elocationid>
      <abstract>
       <abstracttext>
        A novel betacoronavirus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has spread rapidly across the globe since December 2019. Coronavirus disease 2019 (COVID-19) has a significantly higher mortality rate than seasonal influenza and has disproportionately affected older adults, especially those with cardiovascular disease and related risk factors. Adverse cardiovascular sequalae, such has myocarditis, acute myocardial infarction, and heart failure, have been reported in patients with COVID-19. No established treatment is currently available; however, several therapies, including remdesivir, hydroxychloroquine and chloroquine, and interleukin (IL)-6 inhibitors, are being used off-label and evaluated in ongoing clinical trials. Considering these therapies are not familiar to cardiovascular clinicians managing these patients, this review describes the pharmacology of these therapies in the context of their use in patients with cardiovascular-related conditions.
       </abstracttext>
      </abstract>
      <authorlist completeyn="Y">
       <author validyn="Y">
        <lastname>
         Dixon
        </lastname>
        <forename>
         Dave L
        </forename>
        <initials>
         DL
        </initials>
        <affiliationinfo>
         <affiliation>
          Department of Pharmacotherapy &amp; Outcomes Science, Virginia Commonwealth University School of Pharmacy, Richmond, Virginia, USA.
         </affiliation>
        </affiliationinfo>
        <affiliationinfo>
         <affiliation>
          Pauley Heart Center, Division of Cardiology, Department of Internal Medicine, Virginia Commonwealth University, Richmond, Virginia, USA.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Van Tassell
        </lastname>
        <forename>
         Benjamin W
        </forename>
        <initials>
         BW
        </initials>
        <affiliationinfo>
         <affiliation>
          Department of Pharmacotherapy &amp; Outcomes Science, Virginia Commonwealth University School of Pharmacy, Richmond, Virginia, USA.
         </affiliation>
        </affiliationinfo>
        <affiliationinfo>
         <affiliation>
          Pauley Heart Center, Division of Cardiology, Department of Internal Medicine, Virginia Commonwealth University, Richmond, Virginia, USA.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Vecchié
        </lastname>
        <forename>
         Alessandra
        </forename>
        <initials>
         A
        </initials>
        <affiliationinfo>
         <affiliation>
          Pauley Heart Center, Division of Cardiology, Department of Internal Medicine, Virginia Commonwealth University, Richmond, Virginia, USA.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Bonaventura
        </lastname>
        <forename>
         Aldo
        </forename>
        <initials>
         A
        </initials>
        <affiliationinfo>
         <affiliation>
          Pauley Heart Center, Division of Cardiology, Department of Internal Medicine, Virginia Commonwealth University, Richmond, Virginia, USA.
         </affiliation>
        </affiliationinfo>
        <affiliationinfo>
         <affiliation>
          First Clinic of Internal Medicine, Department of Internal Medicine, University of Genoa, Genoa, Italy.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Talasaz
        </lastname>
        <forename>
         Azita
        </forename>
        <initials>
         A
        </initials>
        <affiliationinfo>
         <affiliation>
          Tehran Heart Center, Tehran Province, Iran.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Kakavand
        </lastname>
        <forename>
         Hesam
        </forename>
        <initials>
         H
        </initials>
        <affiliationinfo>
         <affiliation>
          Tehran Heart Center, Tehran Province, Iran.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         D'Ascenzo
        </lastname>
        <forename>
         Fabrizio
        </forename>
        <initials>
         F
        </initials>
        <affiliationinfo>
         <affiliation>
          Division of Cardiology, Department of Medical Science.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Perciaccante
        </lastname>
        <forename>
         Antonio
        </forename>
        <initials>
         A
        </initials>
        <affiliationinfo>
         <affiliation>
          Department of Medicine, University Health Agency Giuliano Isontina, 'San Giovanni di Dio' Hospital, Gorizia, Italy.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Castagno
        </lastname>
        <forename>
         Davide
        </forename>
        <initials>
         D
        </initials>
        <affiliationinfo>
         <affiliation>
          Division of Cardiology, Department of Medical Sciences, University of Turin, Turin, Italy.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Ammirati
        </lastname>
        <forename>
         Enrico
        </forename>
        <initials>
         E
        </initials>
        <affiliationinfo>
         <affiliation>
          Department of Cardiology, Niguarda Hospital, Milan, Italy.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Biondi-Zoccai
        </lastname>
        <forename>
         Giuseppe
        </forename>
        <initials>
         G
        </initials>
        <affiliationinfo>
         <affiliation>
          Department of Medico-Surgical Sciences and Biotechnologies Sapienza', University of Rome, Rome, Italy.
         </affiliation>
        </affiliationinfo>
        <affiliationinfo>
         <affiliation>
          Mediterranea Cardiocentro, Napoli, Italy.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Stevens
        </lastname>
        <forename>
         Michael
        </forename>
        <initials>
         M
        </initials>
        <affiliationinfo>
         <affiliation>
          Division of Infectious Diseases, Department of Internal Medicine, Virginia Commonwealth University, Richmond, Virginia, USA.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Abbate
        </lastname>
        <forename>
         Antonio
        </forename>
        <initials>
         A
        </initials>
        <affiliationinfo>
         <affiliation>
          Pauley Heart Center, Division of Cardiology, Department of Internal Medicine, Virginia Commonwealth University, Richmond, Virginia, USA.
         </affiliation>
        </affiliationinfo>
       </author>
      </authorlist>
      <language>
       eng
      </language>
      <publicationtypelist>
       <publicationtype ui="D016428">
        Journal Article
       </publicationtype>
      </publicationtypelist>
      <articledate datetype="Electronic">
       <year>
        2020
       </year>
       <month>
        04
       </month>
       <day>
        02
       </day>
      </articledate>
     </article>
     <medlinejournalinfo>
      <country>
       United States
      </country>
      <medlineta>
       J Cardiovasc Pharmacol
      </medlineta>
      <nlmuniqueid>
       7902492
      </nlmuniqueid>
      <issnlinking>
       0160-2446
      </issnlinking>
     </medlinejournalinfo>
     <citationsubset>
      IM
     </citationsubset>
    </medlinecitation>
    <pubmeddata>
     <history>
      <pubmedpubdate pubstatus="entrez">
       <year>
        2020
       </year>
       <month>
        4
       </month>
       <day>
        14
       </day>
       <hour>
        6
       </hour>
       <minute>
        0
       </minute>
      </pubmedpubdate>
      <pubmedpubdate pubstatus="pubmed">
       <year>
        2020
       </year>
       <month>
        4
       </month>
       <day>
        14
       </day>
       <hour>
        6
       </hour>
       <minute>
        0
       </minute>
      </pubmedpubdate>
      <pubmedpubdate pubstatus="medline">
       <year>
        2020
       </year>
       <month>
        4
       </month>
       <day>
        14
       </day>
       <hour>
        6
       </hour>
       <minute>
        0
       </minute>
      </pubmedpubdate>
     </history>
     <publicationstatus>
      aheadofprint
     </publicationstatus>
     <articleidlist>
      <articleid idtype="pubmed">
       32282502
      </articleid>
      <articleid idtype="doi">
       10.1097/FJC.0000000000000836
      </articleid>
     </articleidlist>
    </pubmeddata>
   </pubmedarticle>
   <pubmedarticle>
    <medlinecitation owner="NLM" status="Publisher">
     <pmid version="1">
      32282022
     </pmid>
     <daterevised>
      <year>
       2020
      </year>
      <month>
       04
      </month>
      <day>
       13
      </day>
     </daterevised>
     <article pubmodel="Print-Electronic">
      <journal>
       <issn issntype="Electronic">
        1538-3598
       </issn>
       <journalissue citedmedium="Internet">
        <pubdate>
         <year>
          2020
         </year>
         <month>
          Apr
         </month>
         <day>
          13
         </day>
        </pubdate>
       </journalissue>
       <title>
        JAMA
       </title>
       <isoabbreviation>
        JAMA
       </isoabbreviation>
      </journal>
      <articletitle>
       Pharmacologic Treatments for Coronavirus Disease 2019 (COVID-19): A Review.
      </articletitle>
      <elocationid eidtype="doi" validyn="Y">
       10.1001/jama.2020.6019
      </elocationid>
      <abstract>
       <abstracttext label="Importance" nlmcategory="UNASSIGNED">
        The pandemic of coronavirus disease 2019 (COVID-19) caused by the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) presents an unprecedented challenge to identify effective drugs for prevention and treatment. Given the rapid pace of scientific discovery and clinical data generated by the large number of people rapidly infected by SARS-CoV-2, clinicians need accurate evidence regarding effective medical treatments for this infection.
       </abstracttext>
       <abstracttext label="Observations" nlmcategory="UNASSIGNED">
        No proven effective therapies for this virus currently exist. The rapidly expanding knowledge regarding SARS-CoV-2 virology provides a significant number of potential drug targets. The most promising therapy is remdesivir. Remdesivir has potent in vitro activity against SARS-CoV-2, but it is not US Food and Drug Administration approved and currently is being tested in ongoing randomized trials. Oseltamivir has not been shown to have efficacy, and corticosteroids are currently not recommended. Current clinical evidence does not support stopping angiotensin-converting enzyme inhibitors or angiotensin receptor blockers in patients with COVID-19.
       </abstracttext>
       <abstracttext label="Conclusions and Relevance" nlmcategory="UNASSIGNED">
        The COVID-19 pandemic represents the greatest global public health crisis of this generation and, potentially, since the pandemic influenza outbreak of 1918. The speed and volume of clinical trials launched to investigate potential therapies for COVID-19 highlight both the need and capability to produce high-quality evidence even in the middle of a pandemic. No therapies have been shown effective to date.
       </abstracttext>
      </abstract>
      <authorlist completeyn="Y">
       <author validyn="Y">
        <lastname>
         Sanders
        </lastname>
        <forename>
         James M
        </forename>
        <initials>
         JM
        </initials>
        <affiliationinfo>
         <affiliation>
          Department of Pharmacy, University of Texas Southwestern Medical Center, Dallas.
         </affiliation>
        </affiliationinfo>
        <affiliationinfo>
         <affiliation>
          Division of Infectious Diseases and Geographic Medicine, Department of Medicine, University of Texas Southwestern Medical Center, Dallas.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Monogue
        </lastname>
        <forename>
         Marguerite L
        </forename>
        <initials>
         ML
        </initials>
        <affiliationinfo>
         <affiliation>
          Department of Pharmacy, University of Texas Southwestern Medical Center, Dallas.
         </affiliation>
        </affiliationinfo>
        <affiliationinfo>
         <affiliation>
          Division of Infectious Diseases and Geographic Medicine, Department of Medicine, University of Texas Southwestern Medical Center, Dallas.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Jodlowski
        </lastname>
        <forename>
         Tomasz Z
        </forename>
        <initials>
         TZ
        </initials>
        <affiliationinfo>
         <affiliation>
          Pharmacy Service, VA North Texas Health Care System, Dallas.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Cutrell
        </lastname>
        <forename>
         James B
        </forename>
        <initials>
         JB
        </initials>
        <affiliationinfo>
         <affiliation>
          Division of Infectious Diseases and Geographic Medicine, Department of Medicine, University of Texas Southwestern Medical Center, Dallas.
         </affiliation>
        </affiliationinfo>
       </author>
      </authorlist>
      <language>
       eng
      </language>
      <publicationtypelist>
       <publicationtype ui="D016428">
        Journal Article
       </publicationtype>
      </publicationtypelist>
      <articledate datetype="Electronic">
       <year>
        2020
       </year>
       <month>
        04
       </month>
       <day>
        13
       </day>
      </articledate>
     </article>
     <medlinejournalinfo>
      <country>
       United States
      </country>
      <medlineta>
       JAMA
      </medlineta>
      <nlmuniqueid>
       7501160
      </nlmuniqueid>
      <issnlinking>
       0098-7484
      </issnlinking>
     </medlinejournalinfo>
     <citationsubset>
      AIM
     </citationsubset>
     <citationsubset>
      IM
     </citationsubset>
    </medlinecitation>
    <pubmeddata>
     <history>
      <pubmedpubdate pubstatus="entrez">
       <year>
        2020
       </year>
       <month>
        4
       </month>
       <day>
        14
       </day>
       <hour>
        6
       </hour>
       <minute>
        0
       </minute>
      </pubmedpubdate>
      <pubmedpubdate pubstatus="pubmed">
       <year>
        2020
       </year>
       <month>
        4
       </month>
       <day>
        14
       </day>
       <hour>
        6
       </hour>
       <minute>
        0
       </minute>
      </pubmedpubdate>
      <pubmedpubdate pubstatus="medline">
       <year>
        2020
       </year>
       <month>
        4
       </month>
       <day>
        14
       </day>
       <hour>
        6
       </hour>
       <minute>
        0
       </minute>
      </pubmedpubdate>
     </history>
     <publicationstatus>
      aheadofprint
     </publicationstatus>
     <articleidlist>
      <articleid idtype="pubmed">
       32282022
      </articleid>
      <articleid idtype="pii">
       2764727
      </articleid>
      <articleid idtype="doi">
       10.1001/jama.2020.6019
      </articleid>
     </articleidlist>
    </pubmeddata>
   </pubmedarticle>
   <pubmedarticle>
    <medlinecitation indexingmethod="Curated" owner="NLM" status="MEDLINE">
     <pmid version="1">
      32281330
     </pmid>
     <datecompleted>
      <year>
       2020
      </year>
      <month>
       04
      </month>
      <day>
       14
      </day>
     </datecompleted>
     <daterevised>
      <year>
       2020
      </year>
      <month>
       04
      </month>
      <day>
       14
      </day>
     </daterevised>
     <article pubmodel="Print">
      <journal>
       <issn issntype="Print">
        1001-5302
       </issn>
       <journalissue citedmedium="Print">
        <volume>
         45
        </volume>
        <issue>
         6
        </issue>
        <pubdate>
         <year>
          2020
         </year>
         <month>
          Mar
         </month>
        </pubdate>
       </journalissue>
       <title>
        Zhongguo Zhong yao za zhi = Zhongguo zhongyao zazhi = China journal of Chinese materia medica
       </title>
       <isoabbreviation>
        Zhongguo Zhong Yao Za Zhi
       </isoabbreviation>
      </journal>
      <articletitle>
       [Analysis on clinical study protocols of traditional Chinese medicine for coronavirus disease 2019].
      </articletitle>
      <pagination>
       <medlinepgn>
        1232-1241
       </medlinepgn>
      </pagination>
      <elocationid eidtype="doi" validyn="Y">
       10.19540/j.cnki.cjcmm.20200220.501
      </elocationid>
      <abstract>
       <abstracttext>
        To analyze the registered clinical trial protocols of traditional Chinese medicine(TCM) for the prevention and treatment of coronavirus disease 2019(COVID-19), in order to provide information for improving the quality of research design. The website of the Chinese Clinical Trial Registry(www.chictr.org.cn) and the American Clinical Trial Registry(clinicaltrials.gov) were searched to collect protocols of TCM for COVID-19. Documents were screened following the inclusion criteria, and data were extracted in regard to registration date, study objective, type of design, sponsor, patient, sample size, intervention, and evaluation index. Descriptive analysis was conducted. A total of 49 clinical trial protocols of TCM for COVID-19 were included. Primary sponsors were mainly hospitals or universities in places like Hubei, Beijing, Zhejiang and other regions. The implementation units are mainly in Hubei, Guangdong, Zhejiang, Henan and other regional hospitals. The types of study design were mainly experimental studies(40), including 30 randomized parallel controlled trials, 7 non-randomized controlled trials, 2 single arm trials and 1 consecutively recruited trial; besides, there were also 6 observational studies, 2 health service studies and 1 preventive study. The sample size reached a total of 30 562 cases, with a maximum of 20 000 for a single study and a minimum of 30. The 49 trials subjects included healthy people(3), isolation and observation cases(1), suspected cases(10),confirmed COVID-19 patients(31) and COVID-19 recovery patients(4). Of the 31 trials planned to include confirmed COVID-19 patients, 16 protocols no definite disease classification, 3 with a clear exclusion of severe subjects, 4 with common subjects, 2 with light, common or severe subjects, 1 with light and common subjects, 1 with common or severe subjects, 3 with severe subjects, and 1 with severe or critical subjects. The experimental interventions included Chinese patent medicine(Lianhua Qingwen Capsules/Granules, Huoxiang Zhengqi Dropping Pills/Oral Liquid, Babao Dan, Gubiao Jiedu Ling, Jinhao Jiere Granules, Compound Yu-xingcao Mixture, Jinye Baidu Granules, Shufeng Jiedu Capsuless, Shuanghuanglian Oral Liquid, Tanreqing Injection, Xuebijing Injection, Reduning Injection, Xiyanping Injection), Chinese medicinal decoction and taichi. The primary evaluation outcomes mainly included antipyretic time, clinical symptom relief, novel coronavirus nucleic acid turning to negative, conversion rate of severe cases and chest CT. There was a quick response of clinical research on the prevention and treatment of COVID-19 with TCM, with the current registered protocols covers the whole process of disease prevention, treatment and rehabilitation. However, issues need to be concerned, including unclear definition of patient's condition, unclear research objectives, unclear intervention process and inappropriate outcomes, etc. In addition, researchers should consider the actual difficulties and workload of doctors in epidemic response environment, and make effort to optimize the process and improve the operability of research protocols under the principle of medical ethics.
       </abstracttext>
      </abstract>
      <authorlist completeyn="Y">
       <author validyn="Y">
        <lastname>
         Wang
        </lastname>
        <forename>
         Hui
        </forename>
        <initials>
         H
        </initials>
        <affiliationinfo>
         <affiliation>
          Evidence-based Medicine Center, Tianjin University of Traditional Chinese Medicine Tianjin 301617, China.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Jin
        </lastname>
        <forename>
         Xin-Yao
        </forename>
        <initials>
         XY
        </initials>
        <affiliationinfo>
         <affiliation>
          Evidence-based Medicine Center, Tianjin University of Traditional Chinese Medicine Tianjin 301617, China.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Pang
        </lastname>
        <forename>
         Bo
        </forename>
        <initials>
         B
        </initials>
        <affiliationinfo>
         <affiliation>
          Evidence-based Medicine Center, Tianjin University of Traditional Chinese Medicine Tianjin 301617, China.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Liu
        </lastname>
        <forename>
         Chun-Xiang
        </forename>
        <initials>
         CX
        </initials>
        <affiliationinfo>
         <affiliation>
          Evidence-based Medicine Center, Tianjin University of Traditional Chinese Medicine Tianjin 301617, China.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Zheng
        </lastname>
        <forename>
         Wen-Ke
        </forename>
        <initials>
         WK
        </initials>
        <affiliationinfo>
         <affiliation>
          Evidence-based Medicine Center, Tianjin University of Traditional Chinese Medicine Tianjin 301617, China.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Yang
        </lastname>
        <forename>
         Feng-Wen
        </forename>
        <initials>
         FW
        </initials>
        <affiliationinfo>
         <affiliation>
          Evidence-based Medicine Center, Tianjin University of Traditional Chinese Medicine Tianjin 301617, China.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Pang
        </lastname>
        <forename>
         Wen-Tai
        </forename>
        <initials>
         WT
        </initials>
        <affiliationinfo>
         <affiliation>
          Evidence-based Medicine Center, Tianjin University of Traditional Chinese Medicine Tianjin 301617, China.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Zhang
        </lastname>
        <forename>
         Jun-Hua
        </forename>
        <initials>
         JH
        </initials>
        <affiliationinfo>
         <affiliation>
          Evidence-based Medicine Center, Tianjin University of Traditional Chinese Medicine Tianjin 301617, China.
         </affiliation>
        </affiliationinfo>
       </author>
      </authorlist>
      <language>
       chi
      </language>
      <publicationtypelist>
       <publicationtype ui="D016428">
        Journal Article
       </publicationtype>
      </publicationtypelist>
     </article>
     <medlinejournalinfo>
      <country>
       China
      </country>
      <medlineta>
       Zhongguo Zhong Yao Za Zhi
      </medlineta>
      <nlmuniqueid>
       8913656
      </nlmuniqueid>
      <issnlinking>
       1001-5302
      </issnlinking>
     </medlinejournalinfo>
     <chemicallist>
      <chemical>
       <registrynumber>
        0
       </registrynumber>
       <nameofsubstance ui="D004365">
        Drugs, Chinese Herbal
       </nameofsubstance>
      </chemical>
     </chemicallist>
     <supplmeshlist>
      <supplmeshname type="Disease" ui="C000657245">
       COVID-19
      </supplmeshname>
      <supplmeshname type="Protocol" ui="C000705127">
       COVID-19 drug treatment
      </supplmeshname>
      <supplmeshname type="Organism" ui="C000656484">
       severe acute respiratory syndrome coronavirus 2
      </supplmeshname>
     </supplmeshlist>
     <citationsubset>
      IM
     </citationsubset>
     <meshheadinglist>
      <meshheading>
       <descriptorname majortopicyn="N" ui="D000073640">
        Betacoronavirus
       </descriptorname>
      </meshheading>
      <meshheading>
       <descriptorname majortopicyn="N" type="Geographic" ui="D002681">
        China
       </descriptorname>
      </meshheading>
      <meshheading>
       <descriptorname majortopicyn="Y" ui="D000078985">
        Clinical Trial Protocols as Topic
       </descriptorname>
      </meshheading>
      <meshheading>
       <descriptorname majortopicyn="N" ui="D018352">
        Coronavirus Infections
       </descriptorname>
       <qualifiername majortopicyn="Y" ui="Q000188">
        drug therapy
       </qualifiername>
      </meshheading>
      <meshheading>
       <descriptorname majortopicyn="N" ui="D004365">
        Drugs, Chinese Herbal
       </descriptorname>
       <qualifiername majortopicyn="Y" ui="Q000627">
        therapeutic use
       </qualifiername>
      </meshheading>
      <meshheading>
       <descriptorname majortopicyn="N" ui="D006801">
        Humans
       </descriptorname>
      </meshheading>
      <meshheading>
       <descriptorname majortopicyn="N" ui="D008516">
        Medicine, Chinese Traditional
       </descriptorname>
      </meshheading>
      <meshheading>
       <descriptorname majortopicyn="N" ui="D058873">
        Pandemics
       </descriptorname>
      </meshheading>
      <meshheading>
       <descriptorname majortopicyn="N" ui="D011024">
        Pneumonia, Viral
       </descriptorname>
       <qualifiername majortopicyn="Y" ui="Q000188">
        drug therapy
       </qualifiername>
      </meshheading>
      <meshheading>
       <descriptorname majortopicyn="N" ui="D016032">
        Randomized Controlled Trials as Topic
       </descriptorname>
      </meshheading>
      <meshheading>
       <descriptorname majortopicyn="N" ui="D012107">
        Research Design
       </descriptorname>
      </meshheading>
     </meshheadinglist>
     <keywordlist owner="NOTNLM">
      <keyword majortopicyn="N">
       2019-nCoV
      </keyword>
      <keyword majortopicyn="N">
       COVID-19
      </keyword>
      <keyword majortopicyn="N">
       clinical trials
      </keyword>
      <keyword majortopicyn="N">
       protocol registration
      </keyword>
      <keyword majortopicyn="N">
       traditional Chinese medicine
      </keyword>
     </keywordlist>
    </medlinecitation>
    <pubmeddata>
     <history>
      <pubmedpubdate pubstatus="entrez">
       <year>
        2020
       </year>
       <month>
        4
       </month>
       <day>
        14
       </day>
       <hour>
        6
       </hour>
       <minute>
        0
       </minute>
      </pubmedpubdate>
      <pubmedpubdate pubstatus="pubmed">
       <year>
        2020
       </year>
       <month>
        4
       </month>
       <day>
        14
       </day>
       <hour>
        6
       </hour>
       <minute>
        0
       </minute>
      </pubmedpubdate>
      <pubmedpubdate pubstatus="medline">
       <year>
        2020
       </year>
       <month>
        4
       </month>
       <day>
        15
       </day>
       <hour>
        6
       </hour>
       <minute>
        0
       </minute>
      </pubmedpubdate>
     </history>
     <publicationstatus>
      ppublish
     </publicationstatus>
     <articleidlist>
      <articleid idtype="pubmed">
       32281330
      </articleid>
      <articleid idtype="doi">
       10.19540/j.cnki.cjcmm.20200220.501
      </articleid>
     </articleidlist>
    </pubmeddata>
   </pubmedarticle>
   <pubmedarticle>
    <medlinecitation owner="NLM" status="Publisher">
     <pmid version="1">
      32281052
     </pmid>
     <daterevised>
      <year>
       2020
      </year>
      <month>
       04
      </month>
      <day>
       13
      </day>
     </daterevised>
     <article pubmodel="Print-Electronic">
      <journal>
       <issn issntype="Electronic">
        2629-3277
       </issn>
       <journalissue citedmedium="Internet">
        <pubdate>
         <year>
          2020
         </year>
         <month>
          Apr
         </month>
         <day>
          13
         </day>
        </pubdate>
       </journalissue>
       <title>
        Stem cell reviews and reports
       </title>
       <isoabbreviation>
        Stem Cell Rev Rep
       </isoabbreviation>
      </journal>
      <articletitle>
       Mesenchymal Stem Cell Therapy for COVID-19: Present or Future.
      </articletitle>
      <elocationid eidtype="doi" validyn="Y">
       10.1007/s12015-020-09973-w
      </elocationid>
      <abstract>
       <abstracttext>
        "COVID-19" is the word that certainly isn't forgotten by everybody who lives in the first half of the twenty-first century. COVID-19, as a pandemic, has led many researchers from different biomedical fields to find solutions or treatments to manage the pandemic. However, no standard treatment for this disease has been discovered to date. Probably, preventing the severe acute respiratory infection form of COVID-19 as the most dangerous phase of this disease can be helpful for the treatment and reduction of the death rate. In this regard, mesenchymal stem cells (MSCs)-based immunomodulation treatment has been proposed as a suitable therapeutic approach and several clinical trials have begun. Recently, MSCs according to their immunomodulatory and regenerative properties attract attention in clinical trials. After the intravenous transplantation of MSCs, a significant population of cells accumulates in the lung, which they alongside immunomodulatory effect could protect alveolar epithelial cells, reclaim the pulmonary microenvironment, prevent pulmonary fibrosis, and cure lung dysfunction. Given the uncertainties in this area, we reviewed reported clinical trials and hypotheses to provide useful information to researchers and those interested in stem cell therapy. In this study, we considered this new approach to improve patient's immunological responses to COVID-19 using MSCs and discussed the aspects of this proposed treatment. However, currently, there are no approved MSC-based approaches for the prevention and/or treatment of COVID-19 patients but clinical trials ongoing.
       </abstracttext>
      </abstract>
      <authorlist completeyn="Y">
       <author validyn="Y">
        <lastname>
         Golchin
        </lastname>
        <forename>
         Ali
        </forename>
        <initials>
         A
        </initials>
        <identifier source="ORCID">
         http://orcid.org/0000-0001-8661-5046
        </identifier>
        <affiliationinfo>
         <affiliation>
          Department of Clinical Biochemistry and Applied Cell Science, School of Medicine, Urmia University of Medical Sciences, Urmia, Iran. agolchin.vet10@yahoo.com.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Seyedjafari
        </lastname>
        <forename>
         Ehsan
        </forename>
        <initials>
         E
        </initials>
        <affiliationinfo>
         <affiliation>
          Department of Biotechnology, College of Science, University of Tehran, Tehran, Iran.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Ardeshirylajimi
        </lastname>
        <forename>
         Abdolreza
        </forename>
        <initials>
         A
        </initials>
        <affiliationinfo>
         <affiliation>
          Urogenital Stem Cell Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran. r.ardeshiry.62@gmail.com.
         </affiliation>
        </affiliationinfo>
        <affiliationinfo>
         <affiliation>
          SinaCell Research and Product Center, Tehran, Iran. r.ardeshiry.62@gmail.com.
         </affiliation>
        </affiliationinfo>
       </author>
      </authorlist>
      <language>
       eng
      </language>
      <publicationtypelist>
       <publicationtype ui="D016428">
        Journal Article
       </publicationtype>
       <publicationtype ui="D016454">
        Review
       </publicationtype>
      </publicationtypelist>
      <articledate datetype="Electronic">
       <year>
        2020
       </year>
       <month>
        04
       </month>
       <day>
        13
       </day>
      </articledate>
     </article>
     <medlinejournalinfo>
      <country>
       United States
      </country>
      <medlineta>
       Stem Cell Rev Rep
      </medlineta>
      <nlmuniqueid>
       101752767
      </nlmuniqueid>
      <issnlinking>
       2629-3277
      </issnlinking>
     </medlinejournalinfo>
     <citationsubset>
      IM
     </citationsubset>
     <keywordlist owner="NOTNLM">
      <keyword majortopicyn="N">
       COVID-19
      </keyword>
      <keyword majortopicyn="N">
       Clinical trials
      </keyword>
      <keyword majortopicyn="N">
       Coronavirus
      </keyword>
      <keyword majortopicyn="N">
       Immunomodulatory
      </keyword>
      <keyword majortopicyn="N">
       Mesenchymal stem cell
      </keyword>
      <keyword majortopicyn="N">
       Stem cell therapy
      </keyword>
     </keywordlist>
    </medlinecitation>
    <pubmeddata>
     <history>
      <pubmedpubdate pubstatus="entrez">
       <year>
        2020
       </year>
       <month>
        4
       </month>
       <day>
        14
       </day>
       <hour>
        6
       </hour>
       <minute>
        0
       </minute>
      </pubmedpubdate>
      <pubmedpubdate pubstatus="pubmed">
       <year>
        2020
       </year>
       <month>
        4
       </month>
       <day>
        14
       </day>
       <hour>
        6
       </hour>
       <minute>
        0
       </minute>
      </pubmedpubdate>
      <pubmedpubdate pubstatus="medline">
       <year>
        2020
       </year>
       <month>
        4
       </month>
       <day>
        14
       </day>
       <hour>
        6
       </hour>
       <minute>
        0
       </minute>
      </pubmedpubdate>
     </history>
     <publicationstatus>
      aheadofprint
     </publicationstatus>
     <articleidlist>
      <articleid idtype="pubmed">
       32281052
      </articleid>
      <articleid idtype="doi">
       10.1007/s12015-020-09973-w
      </articleid>
      <articleid idtype="pii">
       10.1007/s12015-020-09973-w
      </articleid>
     </articleidlist>
    </pubmeddata>
   </pubmedarticle>
  </pubmedarticleset>
 </body>
</html>